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Nearly one in ten Americans has type 2 diabetes mellitus (T2DM), a major source 
of morbidity, mortality, and healthcare costs.  Most patients with diabetes are treated with 
medicines which may have adverse side effects.  The prevalence of this disease necessitates 
the addition of new, safer compounds to the anti-diabetic arsenal.  The recently reported 
Fatty Acid esters of Hydroxy Fatty Acids (FAHFAs) included eight Palmitic Acid esters 
of Hydroxy Stearic Acid (PAHSA) regioisomers, which may provide a new avenue for 
treatment of T2DM.  In particular, 5- and 9-PAHSA increased insulin secretion, improved 
blood sugar, and decreased adipose tissue inflammation in diabetic mice. While this 
activity is encouraging, much remains unknown about PAHSAs, including the influence 
of chemical connectivity on their activity.  Furthermore, the molecular targets of PAHSAs 
have not been fully elucidated. Until these questions are answered, there can be no hope of 
treating T2DM with an optimized PAHSA analog, nor means to rationally upregulate de 
novo PAHSA synthesis. This resulted in a scalable total synthesis of racemic 5- and 9-
PAHSA, both enantiomers of 9-PAHSA, and preparation of a 30 membered library of 
 v 
PAHSA analogs to probe structure activity relationships. Furthermore, 6 chemical biology 
probes have been prepared to determine in an unbiased manner the molecular targets of 
PAHSAs and their metabolism. 
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Chapter 1: Type 2 Diabetes in the United States and Fatty Acid-
Hydroxy Fatty Acids (FAHFAs), a Novel Family of Anti-Diabetic Lipids 
1. TYPE 2 DIABETES IN THE UNITED STATES OF AMERICA 
1.1 Epidemiology and Economics 
In the United States type 2 diabetes mellitus (T2DM) is a common and costly 
disease. 9.3% of Americans are afflicted with this malady and the prevalence is rising.1 In 
2017, T2DM accounted for $327 billion dollars in health care expenditures in the US, or 
25% of all health care costs.2 Far greater than the financial burden of T2DM is the human 
toll.  
1.2 Mortality and Morbidity 
 A diagnosis of T2DM is associated with a loss of life at all ages, with an earlier age 
of onset resulting in more life-years lost; those diagnosed with T2D at age 20 are 
anticipated to lose 20 years from their lifespan while those diagnosed at 60 are expected to 
give up the ghost 4.5 years prematurely.3 
 In addition to the loss of life, T2DM is a significant cause of morbidity in the US, 
where it is the leading cause of kidney failure, extremity amputation, and adult blindness.1 
T2DM also increases the likelihood of heart attack and stroke.4 Furthermore, elderly 
patients diagnosed with T2DM have a significantly greater risk of cognitive decline 
compared with their non-diabetic counterparts.5 
 All of these medical problems stem from the damage to blood vessels caused by 
chronically elevated blood sugar. However, maintenance of normal blood glucose will be 
discussed before the pathophysiology of T2DM. 
 2 
1.3 Glucose Homeostasis 
Normal blood glucose levels range between 70 to 120 mg/dL and it is vital to 
maintain blood sugar within this range.6 Low blood sugar (hypoglycemia) results in 
neurological deficits and, ultimately, death due to the reliance of the central nervous system 
on glucose as an energy source.6 Though lacking in dentition, the brain has a “sweet tooth;” 
the brain is only 2% of the human body mass, yet consumes 20% of the glucose.7 
Blood glucose declines as a result of normal activity, so something must be done to 
replenish the body’s sugar supply.  As humans lack the enzymatic machinery to 
photosynthesize carbohydrates, neuroregulatory signals drive the individual to eat.6 
The consumption, digestion, and absorption of carbohydrates has been well 
studied.8 Much of the dietary glucose in carbohydrate-rich food is tied up as the dimer 
(maltose), trimer (maltotriose), oligosaccharides, a straight-chain polymer (amylose), or a 
branched-chain polymer (amylopectin). The latter two are commonly referred to as starch. 
After consumption, the above-mentioned di-, tri-, oligo-, and poly-saccharides must 
be broken down to individual glucose monomers to be absorbed. The enzymes responsible 
for the complete hydrolysis of polysaccharides to glucose include salivary amylase and 
pancreatic amylase, glucoamylase, isomaltase, and sucrase. Once liberated, glucose 
monomers are transferred from the lumen of the gut into the enterocytes of the small 
intestine by the sodium-glucose co-tranporter 1 (SGLT1). Glucose then exits from the 
enterocytes into the bloodstream by way of the glucose transporter 2 (GLUT2), leading to 
an increase in blood glucose. 
Insulin is required to return blood sugar to normal levels and there are three primary 
mechanisms leading to increased release of insulin from the pancreas into the blood.  
First, glucose itself may stimulate insulin release. Glucose exits the circulation into 
the β-cells of the pancreas through GLUT2. The increase in cytosolic glucose initiates a 
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cascade of cellular events, ultimately leading to depolarization of the β-cells and exocytosis 
of insulin into the bloodstream.9 
Second, glucose-dependent insulinotropic polypeptide (GIP) also stimulates insulin 
secretion by the pancreas.10-12 As its name suggests, GIP is a polypeptide hormone. After 
eating, a high osmolarity of glucose in the duodenum of the small intestine causes K cells 
in the duodenum and jejunum to release GIP into the general circulation. The GIP receptor 
is a seven-transmembrane-spanning receptor protein located on β-cells of the pancreas. 
Docking of GIP in its receptor ultimately leads to increased insulin secretion. 
Third, glucagon-like peptide-1 (GLP1) also promotes insulin secretion.10, 11 In 
response to a meal, L-cells in the ileum of the small intestine and the large intestine secrete 
the peptide GLP-1 into the serum. The GLP-1 receptor is also located on the surface of 
pancreatic β-cells and the ligand/receptor interaction augments release of insulin. 
GIP and GLP-1 are known as incretins and have a number of shared characteristics. 
Both are released by enteroendocrine cells in the gut, increase insulin secretion, and are 
polypeptides. GIP and GLP-1 are also both rapidly degraded by dipeptidyl peptidase-4 
(DPP4). This physiology will be revisited while discussing T2DM treatment.  
To recapitulate, consumption of dietary carbohydrates leads to elevated serum 
glucose levels and the release of insulin from β-cells of the pancreas by glucose itself and 
the incretins GIP and GLP-1. 
Circulating insulin helps return elevated blood glucose to normal levels by acting 
on the insulin receptor, which is abundant on the surface of fat, muscle, and liver. After 
insulin docks in its insulin receptor, a series of cellular events results in the translocation 
of glucose transporter 4 (GLUT4) from vesicles within the cell to the surface of the cellular 
membrane, permitting glucose to flow down its concentration gradient into the cell while 
concomitantly lowering serum glucose levels.13  
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The importance of adipose GLUT4 in glucose homeostasis cannot be 
overemphasized.14 GLUT4 is downregulated in the fat of overweight and/or diabetic 
humans.15, 16 Furthermore, studies with genetically modified mice showed that knocking 
out GLUT4 specifically in fat cells was sufficient to induce insulin resistance, both in the 
organism and liver and muscle tissues.17 On the other hand, mice with adipocyte specific 
GLUT4 overexpression (AG4OX mice), are protected from diabetes and will be discussed 
further later.  
In summary, to return elevated blood glucose levels to their normal range, there are 
two critical steps: release of insulin by the β-cells of the pancreas and uptake of glucose by 
peripheral tissues like muscle and fat, which make up two-thirds of the body mass.9 The 
two hallmarks of T2DM, and the cause of chronic hyperglycemia, are dysfunction of 
pancreatic β-cells and a dampened response to insulin in the periphery.6, 9  
1.4 T2DM Pathophysiology 
 The single greatest risk factor in T2DM is obesity; over 80% of individuals 
diagnosed with T2DM have a body mass index (BMI) in excess of 30.9 Increase in body 
weight is associated with increased serum free fatty acids,18 a state of low grade  
inflammation,19 and oxidative stress.20 Free fatty acids,21, 22 inflammation,23, 24 and 
oxidative stress25, 26 all contribute to peripheral insulin resistance and impaired insulin 
secretion by β-cells. This dual-edged sword of diminished insulin secretion and decreased 
insulin uptake by fat and muscle leads to higher concentrations of sugar in the blood. Two 
of the most well understood mechanisms of hyperglycemia induced angiopathy include 
advanced glycation end products (AGE)27 and activation of protein kinase C (PKC).28 
 AGEs are formed non-enzymatically when sugars or their degradation products 
form covalent bonds to proteins.27 Mechanistically, this starts when the aldehyde of glucose 
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1 forms a Schiff base 2 with the terminal amino group of a peptide, or with the free amine 
group of an internal lysine. (Figure 1) Tautomerization of 2 gives enol-enamine 3, which 
may tautomerize back to the starting material 2 or irreversibly form the AGE aminoketone 
4 by the Amadori rearrangement. AGEs like 4 then stimulate the receptor of advanced 
glycation end products (RAGE), which leads to the release of cytokines, reactive oxygen 
species, and growth factors vascular endothelial growth factor (VEGF) and transforming 
growth factor β (TGFβ), ultimately causing the vascular damage responsible for the end 
organ damage in T2DM. 
 
Figure 1. Formation of advanced glycation end products from glucose 
 Another mechanism whereby hyperglycemia results in vascular damage is the 
activation of PKC by the secondary messenger diacylglycerol (DAG)28 8. According to 
this model, excess glucose in the cell is converted by glycolysis to acetyl CoA 5, which is 
used as the feedstock to synthesize fatty acids 6. The latter are appended to glycerol-3-
phosphate 7, another product of glucose metabolism, yielding DAG 8 after loss of 
phosphate. DAG then activates PKC, which, like AGE and RAGE, leads to an increase in 
the production of VEGF and TGFβ. In addition, protein plasminogen activator inhibitor-1 
(PAI-1) is also synthesized. These factors ultimately lead to blood vessel destruction and 
the comorbidities commonly observed in patients with T2DM.  
 6 
 
Figure 2. Conversion of glucose to DAG, a potent activator of PKC. 
1.5 T2DM Treatment 
Lifestyle changes (exercise, diet, and weight loss) are recommended for patients 
newly diagnosed with T2DM. Most patients, however, will ultimately need multi-drug 
therapy.29 Unfortunately, many anti-diabetic drugs have adverse side effects. As mentioned 
above, GLP-1 augments insulin secretion and DPP4 degrades GLP-1, suggesting that GLP-
1 agonists and DPP4 inhibitors would be viable pharmacological targets. The FDA has 
approved a number GLP-1 agonists and DPP4 inhibitors; unfortunately, the drugs in these 
two classes have been linked to an increased risk of acute pancreatitis.30, 31 
Thiazoladinediones, another class of medicine used to treat T2DM, have been associated 
with cardiovascular risks.32, 33 These adverse effects underscore the need to develop novel 
agents for the treatment of T2DM. Luckily, a new family of lipids with anti-diabetic 




The groundwork for the discovery of FAHFAs was laid over 20 years before the 
initial report on FAHFAs was released in October of 2014. In 1993 the Kahn lab35 
selectively overexpressed the GLUT4 receptor in murine adipocytes. Phenotypically, these 
Adipocyte specific Glucose transporter OverExpresser (AG4OX) mice were overweight 
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with a 2-3-fold increase in body lipid, but the same amount of body protein compared to 
their wild type (WT) counterparts. Most notably, these overweight AG4OX mice showed 
improved glucose tolerance, with basal (ie, without insulin) glucose transport increased 20-
34-fold and insulin-stimulated glucose transport increased 2-4 fold compared to WT. 
Mechanistically, the improved glucose tolerance and glucose uptake in AG4OX mice was 
attributed to the 6-9-fold increase in the GLUT4 receptor in white adipose tissue (WAT) 
and a 3-5-fold increase in the GLUT4 receptor in brown adipose tissue (BAT). An 
overweight mouse with improved glucose tolerance was an incredible finding as elevated 
body weight is normally correlated with increased risk of T2DM in humans; 80% of 
individuals diagnosed with T2DM are obese. 
  In 1995 the Kahn lab36 built on the previous report and used a radioactive 
uniformly labelled 14C-glucose tracer to follow how glucose was being used in AG4OX 
mice. Surprisingly, a comparison between AG4OX adipocytes and WT adipocytes 
revealed that de novo fatty acid synthesis is markedly elevated in AG4OX adipocytes; fatty 
acid synthesis was increased 31-fold in absence of insulin and 21-fold in the presence of 
insulin in AG4OX fat cells, compared to their wild type counterparts. This raises an 
interesting question: is there a difference in the composition of the lipids that makes these 
fat, overweight mice healthier?    
2.2 FAHFA Discovery 
Working in collaboration, the Kahn and Saghatelian labs34 employed an untargeted 
lipidomic screen, comparing lipids in AG4OX and WT mice. This anylysis revealed the 
presence of a new family of lipids that were elevated 16-18-fold in AG4OX compared to 
WT mice. Further analysis resulted in the discovery that these lipids were fatty acids (FAs) 
condensed to the secondary alcohol of hydroxyfatty acids (HFAs) via an ester linkage. 
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Thus, these new lipids were dubbed FAHFAs. For example (Figure 3), oleic acid (OA) 9 
condenses with 5-hydroxypalmitic acid (5-HPA) 10 to yield 5-oleic acid-hydoxypalmitic 
acid (5-OAHPA) 11. While 5-oleic acid-hydroxypalmitic acid is not true to IUPACs “5-




Figure 3. Synthesis of 5-oleic acid-hydroxypalmitic acid from oleic acid and 5-
hydroxypalmitic acid. 
In the initial report, 16 families were discovered: palmitic acid (PA), palmitoleic 
acid (PO), stearic acid (SA), and oleic acid (OA) crossed with hydroxypalmitic acid (HPA), 
hydroxypalmitoleic acid (HPO), hydroxystearic acid (HSA), and hydroxyoleic acid (HOA) 
in all possible combinations. (Table 1)  
 HPA HPO HSA HOA 
PA PAHPA PAHPO PAHSA PAHOA 
PO POHPA POHPO POHSA POHOA 
SA SAHPA SAHPO SAHSA SAHOA 
OA OAHPA OAHPO OAHSA OAHOA 
Table 1. The 16 FAHFA Families Discovered by Yore et al. 
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Of the sixteen families, palmitic acid-hydroxystearic acids (PAHSAs) were the 
most upregulated in the adipose tissue of AG4OX mice. Yore et al found that the PAHSA 
family included 8 regioisomers, with the ester located at carbon 5, 7, 8, 9, 10, 11, 12, and 
13). (A subsequent study by Kuda and co-workers found 6-PAHSA, increasing the number 
to 9 regioisomers). Of the PAHSA regioisomers, 5- and 9-PAHSA stood out as 5-PAHSA 
12 was the regioisomer most downregulated in the serum and fat of insulin resistant mice 
while 9-PAHSA 13 was the most upregulated in AG4OX mice (Figure 4).  
 
Figure 4. 5- and 9-PAHSA, the most notable PAHSA regioisomers with the greatest 
change in concentration. 
In mice, acute gavage with 5- and 9-PAHSA gavage led to increased serum 
concentration, improved glycemia, improved glucose tolerance, increased GLP-1 
secretion, increased insulin, and decreased inflammation. 
In vitro studies with human pancreatic β-cells showed that PAHSAs augmented 
insulin secretion, while PAHSA treated stc-1 enteroendocrine cells increased glp-1 
secretion in a dose dependent manner. Furthermore, PAHSA treatment increased 3T3-L1 
adipocyte specific insulin-stimulated glucose transport by enhancing GLUT4 
translocation. It is noteworthy that neither palmitic acid, nor 9-HSA showed this activity. 
Mechanistically, gpr120 (aka free fatty acid receptor 4, FFAR4) was determined to be the 
target of PAHSAs, with both 5- and 9-PAHSA activating gpr120 in a dose-dependent 
manner. Previous work by Oh and co-workers showed that gpr120 stimulation increases 
GLUT4 translocation.  
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Most importantly, PAHSAs were found in humans and that serum and fat 
concentration were higher in insulin sensitive individuals than in their insulin resistant 
counterparts. These data suggest that PAHSAs play an important role in human glucose 
homeostasis. It is also noteworthy that Yore et al also found FAHFAs in food. 
2.3 Developments Since the Initial Report 
Since the initial FAHFA report in 2014, a number of monographs have appeared, 
expanding the FAHFA literature. This work may be divided into 5 fields: 1) FAHFAs and 
inflammation, 2) FAHFA hydrolases, 3) FAHFAs in unexpected places, 4) FAHFA 
analysis, and 5) FAHFA synthesis (the subject of chapter 2), 
2.3.1 FAHFAs and Inflammation 
As mentioned above, the anti-inflammatory activity is of particular importance as 
the development of insulin resistance and T2DM are associated with chronic low grade 
inflmmation. Since the initial findings by Yore et al, two groups have shared additional 
reports on the anti-inflammatory activity of FAHFAs. 
Lee and co-workers37 explored the utility of PAHSAs in a murine model of 
ulcerative colitis (UC). UC is a chronic colonic inflammatory condition and is commonly 
modeled in mice with dextran sulfate sodium (DSS). In their study, Lee et al found that 
pretreatment with a combination of 5- and 9-PAHSA followed by the DSS insult decreased 
weight loss and improved colitis score when compared to mice treated with vehicle. 
Furthermore, they observed in the PAHSA treatment group a dampening of T cell 
activation and a decrease in pro-inflammatory cytokines and chemokines compared with 
the control group. Mechanistically, they concluded that gpr120 was partially responsible 
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for these effects, further supporting the conclusions Yore et al drew with respect to gpr120 
functioning as a FAHFA target. 
Subsequently, Kuda et al38 discovered a new FAHFA, 13-docosahexaenoic acid-
hydroxylinoleic acid (13-DHAHLA) 14, with more potent anti-inflammatory activity than 
9-PAHSA in a LPS-stimulated RAW264.7 macrophage model. In addition to 13-
DHAHLA, the group also found two additional new FAHFAs, 9-DHAHLA 15 and 14-
docosohexaenoic acid-hydroxydocosohexaenoic acid (14-DHADHA) 16, in the serum and 
fat of humans and mice that received supplemental DHA and eicocospentaenoic acid 
(EPA). (Figure 5) Surprisingly, no FAHFAs with EPA, nor HEPA were disclosed.  
 
Figure 5. Three new FAHFAs found in mice and humans who received supplemental 
DHA an EPA. 
2.3.2 FAHFA Hydrolases 
 In the years following the discovery, little has been learned about FAHFA 
metabolism. A specific enzyme responsible for the acylation of HFAs remains elusive, but 
three FAHFA hydrolases have been reported. 
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Parsons and co-workers39 used activity-based protein profiling (ABPP) to discover 
the first two FAHFA specific hydrolazes. Pulldown experiments and proteomic analysis 
identified androgen-induced gene 1 protein (AIG1) and androgen-dependent TFPI-
regulating protein (ADTRP) as potential FAHFA hydrolases. The Saghatelian and Cravatt 
labs found that AIG1 and ADTRP were threonine hydrolases that preferentially targeted 
the ester bond of FAHFAs. Mutation studies proved the key residues were thr48/his134 
and thr47/his131 for AIG1 and ADTRP, respectively. The hydrolytic activity of the two 
enzymes was tested against a broad lipid library that included FAHFAs (5-, 9-, and 12-
PAHSA; 5-, 9-, 12-, and 13-POHSA; 5-, 9-, 12-, and 13-SAHSA;  and 5-, 9-, 12-, and 13-
OAHSA), triacylglycerol, diacylglycerol, monoacylglycerol, cholesterol ester, 
phoshatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositiol, 
phosphatidylglycerol, phosphatidic acid, and lysophospholipids. AIG1 and ADTRP 
selectively hydrolyzed FAHFA over other members of the library; furthermore, the rate of 
FAHFA hydrolysis was regioselective with the hydrolysis rate increasing as the ester 
position was located further from the carboxylic acid head of the FAHFA.  
Later in 2016, Kolar and co-workers40 discovered a 3rd FAHFA-specific hydrolase, 
carboxyl ester lipase (CEL). In contrast with the previous report on AIG1 and ADTRP, 
which used ABPP to find the enzymes of interest, Kolar and colleagues investigated tissue 
lysates (pancreas, spleen, brain, kidney, liver, brown adipose tissue, perigonadal white 
adipose tissue, and subcutaneous white adipose tissue) for their ability to hydrolyze 9-
PAHSA. Pancreatic tissue was by far the most active, with the rate of hydrolysis over an 
order of magnitude higher than the next most active tissue screened. The pancreatic 
proteome was then divided into membrane and soluble fractions, with the membrane 
portion containing most of the hydrolytic activity. Screening the pancreatic membrane with 
inhibitors suggested that the enzyme of interest was a serine hydrolase, narrowing the likely 
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targets to CEL, pancreatic lipase (PNLIP), and pancreatic lipase-related protein 2 
(PNLIPRP2). Sodium taurocholate augments the hydrolytic activity of CEL while 
dampening the activity of PNLIP and PNLIPRP2. Addition of sodium taurocholate to the 
pancreatic membrane fraction increased the rate with which 9-PAHSA was hydrolyzed, 
confirming that CEL was the culprit. HEK293T cells were transfected with CEL and the 
cell lysate was screened for hydrolytic activity with the same 31 compound lipid library 
that was used with AIG1 and ADTRP. Surprisingly, CEL hydrolyzed FAHFAs at nearly 
double the rate of AIG1 or ADTRP and with the same regioselective preference for 
FAHFAs with the ester bond further from the carboxylic acid. Humans with maternity-
onset diabetes of the young type 8 (MODY8) are known to have a mutated CEL enzyme 
and the MODY8 varient of CEL was twice as active as the human wild type variant. The 
influence the MODY8 CEL variant has on patient FAHFA levels merits further 
exploration. 
2.3.3 FAHFAs in unexpected places 
Yore et al first found FAHFAs in mice and men. Subsequent studies have found 
FAHFA in marsupials, microbes, and milk. Two groups have even found FAHFAs 
incorporated into triacylglycerols (TAGs). 
 McLean and co-workers41 were the first to observe FAHFAs in TAGs. While 
analyzing the lipid content of the paracloacal glands of the brushtail possum, a marsupial 
native to Australia, they found 150 TAG-FAHFAs. The other acyl groups appended to the 
glycerol backbone were medium chain fatty acids (C7 to C9) while the FAHFA moiety 
contained between 33-36 carbons and 2-3 degrees of saturation. Position of the FAHFA 
ester and olefins was not discussed, nor the position of the acyl groups on the glyceride 
backbone. It is noteworthy that other fat depots in the abdomen and around the kidney had 
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a lipid distribution similar to mammals and did not include any TAG-FAHFAs. The authors 
suspected that these different lipids stored in the paracloacal glands function as a 
semiochemicals, permitting olfactory communication between animals. 
Subsequently, Kajikawa and colleagues42 of the Fukuzawa lab found FAHFA 
TAGs in a genetically modified strain of the microalgal diatom Chatoceros gracilis. The 
Fukuzawa lab was attempting to synthesize the industrially important hydroxyfatty acid 
ricinoleic acid in a carbon neutral manner. To achieve this end, they introduced the gene 
fatty acid hydratase (FAH) from the fungus Claviceps purpurea into the diatom C. gracilis. 
FAH is the enzyme that converts oleic acid to ricinoleic acid via a homoallylic oxidation 
at C12. Under photosynthetic, chemoautotrophic conditions, up to 11% of the lipid content 
of genetically modified C gracilis contained ricinoleic acid. 70% of the ricinoleic acid were 
FAHFA triglycerides, either as ricinoleic acid-hydroxyoleic acid (RAHOA) TAG 17, with 
a free-hydroxyl group, or PAHOA, or POHOA 18. (Figure 6) The FAHFAs were located 
uniquely at the C1/3 position of the triglyceride backbone with myristic acid, PA, or PO at 
the other two positions of glycerol. 
 
Figure 6. Two types of FAHFA TAGs discovered in a genetically modified strain of C 
gracilis. 
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Most interestingly, FAHFAs were found in human milk. In 2018, Brezinova and 
coworkers43 investigated breast milk for the presence of FAHFAs. The first sample was 
acquired at 72 hours after birth and FAHFAs were still present 9 months after birth. All 
known FAHFAs were present, with a markedly higher concentrations of 5-PAHSA in milk 
compared to 5-PAHSA levels previously observed in sera and other tissues. Surprisingly, 
total PAHSA levels and 5-PAHSA levels were higher in the breast milk of lean mothers 
than in obese mothers. Furthermore, chiral chromatography revealed that R-5-PAHSA was 
the major enantiomer, which is consistent with our findings that R-9-PAHSA was the major 
enantiomer in AG4OX mice.44 It was also noteworthy that they observed 13-DHAHLA in 
a mother who was taking omega-3 fatty acid supplements. Brezinova and colleagues 
supported their human studies with mouse work. Murine milk also contained elevated 5 
PAHSA concentrations compared to other tissues and serum. Furthermore, gavage with 5 
PAHSA at increasing doses (5, 10, 20 mg/kg) led to proportional increases in serum levels, 
suggesting that 5-PAHSA is absorbed from the GI tract into the serum of the newborn. The 
role 5-PAHSA plays in the development of the newborn remains to be determined. 
2.3.4 FAHFA Analysis 
While the original LC-MS method allowed for the discovery of FAHFAs, there 
have been some important contributions in FAHFA analysis, permitting automatic 
annotation, quicker run time, and heightened sensitivity. 
Ma and colleagues45 developed a freely available, in silico MS/MS library, allowing 
for rapid, automatic annotation. Their library contained predicted fragmentation for over 
1,000 possible FAHFAs. Furthermore, they validated their method by applying it to a 
complex mixture of lipids extracted from egg yolk, where they discovered 4 new FAHFA 
oleaic acid-hydroxy linoleic acid (OAHLA), linoleic acid-hydroxyoleic acid (LAHOA), 
 16 
linoleic acid-hydroxylinoleic acid (LAHLA), and alpha-linolenic acid-hydroxyoleic acid 
(ALAHOA), though the regioisomers were not specified. 
López-Bascón and coworkers46 contributed an automated workflow for automated 
solid phase extraction (SPE) and LC-MS analysis of FAHFA levels in serum. In addition 
to the convenience of automation, their method also cut down the time to only 25 minutes 
per sample, with 20 minutes for analysis and 5 minutes to re-equilibrate the column 
between injections. While this seems to be an advantage over the 90-minute run time 
described by Zhang et al,47 the Lopez-Bascon separates FAHFA families, but not 
regioisomers. Their analysis showed that FAHFA family serum concentrations vary based 
on BMI and glycemic state; normoglycemic individuals had higher POHPO levels than 
their prediabetic counterparts and diabetics had higher PAHPA concentrations than their 
prediabetic counterparts; POHPA levels were elevated in normal weight individuals than 
in those who were overweight. 
Zhu et al48 combined strong anion exchange-solid phase extraction with chemical 
labelling and ultra high performance liquid chromatography/mass spectrometry to give the 
lengthy acronym SAX-SPE-CL-UHPLC/MS. Impressively, chemical labelling of 
FAHFAs 19 with 2-dimethylaminoethylamine 20 and 2-chloromethylpyridinium iodide 21 
gave the corresponding amide 22 with 10- to 100-fold in detection sensitivity by MS. 
(Figure 7)  
 
Figure 7. Zhu and colleagues chemical labelling of FAHFAs for improved MS 
sensitivity.  
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This is a major improvement for a class of molecules that are present at low 
concentrations in serum and tissue. It is also noteworthy that their chromatographic method 
allowed for separation of regioisomers in only 20 minutes. With this method in hand, they 
discovered that 9- and 13-PAHSA and 12- and 13-SAHSA were decreased in the serum of 
breast cancer patients compared to healthy controls. This raises interesting questions about 




Chapter 2: PAHSA and SAR Library Synthesis* 
2.1 FAHFA PRIOR SYNTHESES 
When we initiated our FAHFA research program, there were only two reported 
synthetic routes to FAHFAs. The Yore34 synthesis of 5-PAHSA 12 began with the addition 
of pent-4-en-1-ylmagnesium bromide 24 to tetradecanal 23, providing olefin-alcohol 25. 
The secondary alcohol of 25 was acylated with palmitic anhydride, affording olefin-ester 
26. The synthesis concluded with an ozonolyis and Pinnick oxidation to yield 5-PAHSA 
12. Drawbacks to this route include the modest overall yield, the expensive aldehyde 
starting material, and poor atom economy in the acylation step. Furthermore, the 
experimental was poorly written, with identical characterization data for different 
compounds (12 and 26) and the oxidant in the Pinnick oxidation written as sodium 
hypochlorite (NaOCl), rather than sodium chlorite (NaClO2) 
 
Figure 8. Synthesis of 5-PAHSA originally reported by Yore and co-workers. 
                                                 
* Some of the contents of this chapter was based on Nelson, A.T.; Kolar, M.J.; Chu, Q.; Syed, I.; Kahn, 
B.B.; Saghatelian, A.; Siegel, D. Stereochemistry of Endogenous Palmitic Acid Ester of 9-Hydroxystearic 
Acid and Relevance of Absolute Configuration to Regulation. J. Am. Chem. Soc. 2017, 139, 4943-4947. 
Nelson and Kolar contributed equally to this work. Nelson developed the hypothesis for the project, 
planned and executed the synthesis, characterized all compounds, and co-wrote the manuscript. 
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The other previously described FAHFA synthesis was in a 2015 patent.49 (Figure 
9) In the first step nonane-1,9-diol 27 was monoprotected as THP ether 28 with PPTS and 
THP. The primary alcohol of 28 was oxidized with PCC to aldehyde 29. Addition of 
nonylmagnesium bromide to the aldehyde of 29 gave secondary alcohol 30, which was 
acylated with acetic anhydride, giving THP-acetate 31. Doubly protected 31 was converted 
to 9-HSA 35 by a four step sequence involving removal of the THP group with PPTS and 
ethanol, oxidation of the primary alcohol 32 to the aldehyde 33 with PCC, then oxidation 
of the aldehyde to the carboxylic acid 34 under Pinnick's condition, and, finally, cleavage 
of the acetate of 34 with lithium hydroxide, yielding 9-HSA 35. The carboxylic acid of 9-
HSA 35 was protected with alpha-bromoketone 36 and dicyclohexylamine, yielding ester-
alcohol 37. The secondary alcohol of 37 was acylated with palmitoyl chloride and DMAP; 
subsequent chemoselective ester cleavage with zinc and acetic acid gave 9-PAHSA 13. 
The synthesis suffers from a high step count, low yield (<1 %), multiple protecting group 




Figure 9. The second reported FAHFA synthesis. 
Concurrent with our work on the synthesis of FAHFAs, Balas and coworkers50 
developed a synthesis of PAHPA and OAHPA regioisomers. (Figure 10) First, commercial 
olefin-alcohol 39 was protected as the corresponding TBS ether 40, whose terminal olefin 
was oxidized to epoxide 41 with mCPBA. The authors noted that reversing the order of 
protection/oxidation steps gave lower yields. The terminal epoxide of 41 was opened with 
lithium acetylide 42 and boron trifluoride-diethyl etherate, yielding homopropargylic 
alcohol 43. The alkyne of 43 was exhaustively reduced in good yield to alcohol 44 with 
hydrogen and Rosenmund's catalyst. Surprisingly, when palladium on carbon was used in 
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lieu of Rosenmund's catalyst, yields were markedly lower. The secondary alcohol of 44 
was then esterified under the conditions of Steglich, affording ester 45. The silyl group was 
deprotected with TBAF to give primary alcohol 46. The synthesis was concluded with a 
Jones oxidation of primary alcohol 46 to the corresponding carboxlyic acid 47. This route 
was also used to synthesize 5-PAHPA, 5- and 9-OAHPA, and 10-OAHSA.  
 
Figure 10. The Balas acetylide approach to 9-PAHPA. 
Balas and colleagues also prepared 7-PAHPA, PAHSA, OAHPA, and OAHSA in 
a similar, though not identical, manner. (Figure 11) The left fragment was prepared by 
protecting the primary alcohol 48 as TBS ether 49. The two pieces were connected when 
the lithium acetylide 50 added to the terminal epoxide of 51, yielding homopropargylic 
alcohol 52. The end game for the 7-series was identical to the final steps in Figure 10 with 
exhaustive reduction to 53, Steglich esterification to 54, silyl deprotcation to 55, and Jones 
oxidation completing the synthesis of 7-PAHSA 56.  
 22 
 
Figure 11. The Balas acetylide approach to 7-PAHSA. 
While the route of Balas co-workers resulted in the synthesis of a number of new 
FAHFAs, there are some limitations, including utilization of super-stoichiometric 
quantitites of toxic chromium in the final step, and small scale. 
Also concurrent with our work, Kuda and coworkers38 reported a synthesis of 13-
DHAHLA 14. (Figure 12) Their synthesis begins with a soybean lipooxygenase catalyzed 
conversion of linoleic acid to 13-HODE 57. Steglich esterification of 57 with DHA yielded 
13-DHAHLA 14 after purification via HPLC. Surprisingly, the experimental procedures 




Figure 12. Kuda and co-workers synthesis of 13-DHAHLA. 
2.1 SCALABLE SYNTHESIS OF 5- AND 9-PAHSA 
We sought to develop a concise, scalable synthesis that avoided using toxic metals 
as we needed multiple grams of 5- and 9-PAHSA for in vitro and in vivo studies. Owing to 
the prohibitive expense of tetradecanal, our synthesis of 5-PAHSA began with the 
oxidation of 1-tetradecanol 58 to tetradecanal 23. Oxidation with TEMPO and DAIB at 
ambient temperature under the conditions of De Mico and coworkers51 resulted in clean 
and complete conversion of decanol to decanal. Other conditions explored included tempo 
with NCS52 or trichloroisocyanuric acid53 as terminal oxidant, both of which had a more 
tedious workup and gave a product of lower purity. The Parikh-Doering54 and Swern55 
oxidations, while effective, were disagreeable due to the smelly dimethyl sulfide evolved. 
Crude aldehyde 23 was used directly in the next step, where addition of Grignard 24 
afforded olefin-alcohol 25. The secondary alcohol of 25 was acylated to ester 26 in good 
yield with commercial palmitoyl chloride in lieu of palmitic anhydride, improving the atom 
economy of this step.  
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Figure 13. Our synthesis of racemic 5-PAHSA. 
The ozonolysis of the terminal olefin of 26 proved non-trivial. The ozonolytic 
conditions reported by the Drussault lab56 with NMMO as an additive were singular in their 
ability to fully suppress formation of the secondary ozonide. According to the Criegee 
mechanism57 (Figure 14), ozonolysis begins with a 1,3 dipolar cycloaddition of ozone with 
olefin 59, forming secondary ozonide 60. Decomposition gives formaldehyde 61 and 
carbonyl oxide 62. Another 1,3 dipolar cycloaddition yields secondary ozonide 63. These 
species are known to be shock-sensitive and potentially explosive and should be avoided, 
particularly when working on scale.  
 
Figure 14. The Criegee mechanism of ozonolyis. 
The Drussault lab56 proposes that NMMO 64 adds into carbonyl oxide 62, forming 
a tetrahedral intermediate 65, which decomposes to aldehyde 66, NMO 67, and oxygen. 
(Figure 15) Conveniently, aqueous workup removed all NMO and the crude aldehyde was 
used without further purification. 
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Figure 15. Prevention of secondary ozonide formation with NMMO as per Drussault. 
Other methods for the ozonlysis of 26 were explored, including formic acid with 
hydrogen peroxide,58 quenching with dimethyl sulfide59 or triphenylphosphine,60 with 
pyridine as an additive,61 and running the reaction in wet acetone62 or acetonitrile.63 All of 
these other methods formed notable quantities of secondary ozonide. These data are 
summarized in Table 2. 
Ozone + Reactant Solvent Temp (°C) Product:2° Ozonide 
NMMO, then NaClO2 DCM 0 100:0 (94% yield) 
PPh3 (2 eq) DCM:MeOH (80:20) 0 95:5 
NaClO2 Acetone:water 0 93:7 
NaClO2 Acetonitrile:water 0 90:10 
Me2S (40 eq) DCM -78 86:14 
Pyridine DCM -78 85:15 
Formic acid, H2O2 Formic acid Reflux 79:21 
Table 2. Conditions explored for the ozonolysis of terminal alkene 26. 
With a safe method to cleave 26 on decagram scale, the synthesis of 5-PAHSA was 
concluded with Pinnick oxidation of the crude aldehyde to 5-PAHSA 12. The final step 
reaction has been successfully cacrried out to afford over 20 g of final product in a single 
batch in good overall yield. 
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9-PAHSA was synthesized in an analogous manner, (Figure 16) using 1-decanol 
68 as the starting alcohol and non-8-en-1-ylmagnesium bromide 70 as the Grignard 
reagent. We found it was important to use freshly prepared decanal 69 rather than 
commercial decanal; even new bottles of decanal gave a more complex mixture after 
addition of non-8-en-1-ylmagnesium bromide 70. The olefin-alcohol 71 was then acylated 
with palmitoyl chloride to give olefin-ester 72, which was oxidized under the optimized 
conditions to yield 9-PAHSA 13 in 4 steps and good overall yield. 
 
Figure 16. Our racemic synthesis of 9-PAHSA. 
2.1.1 Biological Studies With 5- and 9-PAHSA 
 With decagrams of 5- and 9-PAHSA in hand, we have been able to conduct a 
number of in vivo and in vitro studies. Two of these have been published. 
In the first study, Vijayakumar and colleagues64 explored the effects of 9-PAHSA 
in the context of adipocyte specific knockout of carbohydrate response element binding 
protein mice (AdChREBP KO). In humans, lower levels of ChREBP in adipocytes and 
decreased de novo lipogenesis are linked to insulin resistance. To further explore this 
phenomenon, we selectively knocked out ChREBP in adipocytes in mice, generating 
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AdChREBP KO mice. Compared to controls, AdChREBP KO mice were insulin resistant 
and the liver, muscle, and adipose tissue showed attenuated insulin action. AdChREBP KO 
adipocytes had similar GLUT4 levels to WT mice, but GLUT4 translocation and 
exocytosis were blunted. Furthermore, AdChREBP KO adipose tissue showed more 
inflammation and serum had lower PAHSA concentrations, compared to WT controls. 
Incredibly, AdChREBP KO mice supplemented with 9-PAHSA saw a complete reversal 
of the previously observed insulin resistance, adipose tissue inflammation, impaired 
glucose transport, and GLUT4 transport. 
In the second report, Syed et al,65 we investigated the chronic effects of 5- and 9-
PAHSA administration via minipump over several months. This is in contrast with the 
Yore report which only studied the acute effects of 5- and 9-PAHSA on glucose 
homeostasis. Chronic PAHSA administration to chow fed mice increased serum and fat 
tissue PAHSA levels, improved glucose tolerance and insulin sensitivity, and augmented 
insulin and GLP-1 secretion, compared with control mice. PAHSA treated mice also had 
reduced inflammation in adipose tissue, with decreased in pro-inflammatory macrophages 
and no change in anti-inflammatory macrophages. Mechanistically, gpr40 (free fatty acid 
receptor 1, FFAR1) was reported for the first time to play an important role in PAHSA 
activity. Hek293 cells transfected with murine gpr40 were used to show that 9-PAHSA 
activates gpr40 in a dose-dependent manner; furthermore, blockade of gpr40 genetically 
(siRNA) and pharmacologically (gw1100) attenuated agonism of 9-PAHSA at this 
receptor, confirming that gpr40 is a target of 9-PAHSA. It is worth noting that 
gpr40/FFAR1 is considered a promising target for the treatment of T2DM. 
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2.2 SYNTHESIS OF ENANTIOPURE 9-PAHSA 
While these animal studies with racemic 5- and 9-PAHSA provided exciting 
results, an outstanding question remained: what is the stereochemistry of endogenously 
produced 9-PAHSA? In order to answer this question, we needed to synthesize enantiopure 
standards. (Figure 17) In our synthesis,44 we chose a chiral pool approach, employing 
inexpensive S-(+)- and R-(-) epichlorohydrin as the source of chirality for R- and S-9-
PAHSA, respectively. The synthesis of R-9-PAHSA began with copper catalyzed addition 
of 7-oectenylmagneisum bromide 74 into the unsubstituted end of S-(+)-epichlorohydrin, 
giving chlorohydrin 73. An intramolecular Williamson ether synthesis followed converted 
chlorohydrin 73 to terminal epoxide 76 via a 3-exo-tet cyclization, which is favored 
according to Baldwin's rules.66 Octylmagnesium chloride was added with catalytic copper 
iodide, yielding secondary alcohol 71. Relay of chirality was confirmed by derivatization 
as the corresponding S-9-acetylmandelate ester; the diastereomeric ratio proved to be 
greater that 99:1, with no trace of racemization. The synthesis terminates using the same 
steps mentioned above. Alcohol 71 was acylated with palmitoyl chloride to give ester 72, 
which was subjected to ozonolysis and Pinnick oxidation, yielding enantiopure R-9-
PAHSA R-13 in 55% yield. S-9-PAHSA S-13 was synthesized in 61% overall yield in an 
analogous manner starting with R-(-)-epichlorohydrin R-73 in lieu of S-(+)-
epichlorohydrin S-73.  
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Figure 17. Our synthesis of enantiopure S- and R-9-PAHSA. 
Some of the R- and S-9-PAHSA were saponified to R- and S-9-hydroxystearic acid, 
respectively, with potassium hydroxide. (Figure 18) It should be noted that previous efforts 
to resolve 9-HSA enzymatically only provided 9-HSA modest optical purity (54% ee).  
 
Figure 18. Synthesis of enantiopure S- and R-9-HSA by saponifying 9-PAHSA. 
2.2.1 Biological Testing with Enantiopure 9-PAHSA 
With enantiopure 9-PAHSA in hand a number of analytical methods to resolve the 
enantiomers were explored. (Figure 19) First, derivatization of 9-PAHSA as the 
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corresponding methyl ester 78 followed by chiral GC resolution failed, likely owing to the 
large molecular weight. Secondly, we used S-1-phenylethan-1-amine to prepare amide 79. 
The diastereomers formed would not separate under any of the liquid chromatographic 
conditions explored, nor was any splitting observed in the 1H NMR spectrum; in both 
cases, this was likely due to the distance between the two chiral centers.  
 
Figure 19. Efforts towards the resolution of 9-PAHSA and its derivatives. 
Having exhausted the resources at our disposal to separate the 
enantiomers/diasteriomers, we turned to the chiral screening service offered by 
Phenomenex (Torrance, CA). We provided rac- and R-9-PAHSA and, after screening 6 
chiral columns (cellulose-1, -2, -3, and -4, and amylose-1, and -2) and 3 solvent systems 
(water/acetonitrile, hexane/ethanol, and methanol/isopropanol), they found that the Lux 5 
um cellulose-3 column with methanol/isopropanol/trifluoroacetic acid (90:10:0.1) 
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successfully resolved the enantiomers. One drawback of this solvent system is that TFA is 
not compatible with our LC-MS, thus we had to further optimize the solvent conditions. 
We found that methanol/water/formic acid (96:4:0.1) provided separation of the 
enantiomers, with S-9-PAHSA eluting first at 17.4 min and R-9-PAHSA eluting at 20.2 
min. Regrettably, the formic acid led to a 25-fold decrease in sensitivity. Thus, to determine 
the endogenous stereoisomer of 9-PAHSA, we used perigonadal gonadal white adipose 
tissue from AG4OX mice as this lipid depot boasts the highest concentrations of 9-PAHSA 
of all tissues sampled.  
The Kahn lab generously donated AG4OX pgwat. After Bligh Dyer extraction and 
separation of neutral lipids with a solid phase exstraction cartridge, we resolved the 
enantiomers using our optimized conditions via chiral LC-MS. The data show R-9-PAHSA 





Figure 20. Resolution of 9-PAHSA enantiomers and abundance in AG4OX PGWAT 
At first glance, it would appear that there are also appreciable amounts of S-9-
PAHSA, however, further studies showed that R-10-PAHSA co-elutes with S-9-PAHSA 
under these conditions 
In addition to showing that R-9-PAHSA is the predominant enantiomer found in 
AG4OX mice, we also discovered two of the mechanisms for this phenomenon. 9-PAHSA 
is synthesized by condensing 9-hydroxystearic acid with palmitic acid and hydrolysis of 9-
PAHSA yields 9-HSA and PA. In previous studies, CEL was the most potent of the 3 
FAHFA hydrolases that have been discovered. When 9-PAHSA was incubated with 
pancreatic lysate (Figure 21A) or HEK293T transfected with CEL (Figure 21B), S-9-
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PAHSA was selectively hydrolyzed in preference to R-9-PAHSA, explaining, in part, a 
reason for the predominance of r-9-PAHSA in AG4OX mice. 
 
Figure 21. Asymmetric hydrolysis of 9-PAHSA and acylation of 9-HSA. A) Pancreatic 
lysate hydrolyses S-9-PAHSA more rapidly than R-9-PAHSA. B) HEK293T 
cells transfected with CEL hydrolyses S-9-PAHSA more rapidly than R-9-
PAHSA. C) HEK293T cells preferentially acylate R-9-HSA compared with 
S-9-HSA 
As mentioned previously, 9-PAHSA may be biosynthesized via condensation of 9-
HSA with palmitic acid. The enzyme responsible for this activity remains unknown, but a 
previous report showed that 17 carbon hydroxyheptadecanoic acid was acylated in cells to 
form the corresopnding FAHFA. In a similar manner, we incubated HEK293T cells with 
either R-9-hsa or S-9-HSA, then analyzed the cells for 9-PAHSA. We found nearly twice 
as much 9-PAHSA when cells were incubated with R-9-HSA than S-9-HSA. (Figure 21C) 
These data suggest that FAHFAs are formed stereoselectively by an enzymatic process. In 
summary, R-9-PAHSA is the major enantiomer in mice for at least two reasons: 1) S-9-
PAHSA is preferentially hydrolyzed by CEL and 2) R-9-HSA is selectively acylated by an 
as yet undiscovered enzyme. 
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2.3 PAHSA SAR LIBRARY 
FAHFAs have a wealth of promising biological activity, however the relationship 
between FAHFA structure and activity (SAR) has never been logically examined. A few 
of the previously mentioned studies provided insight into the parameters worth exploring. 
Our work with showed that the stereochemistry of 9-PAHSA and 9-HSA effects its cellular 
processing.44 The work by Parsons39 and Kolar40 showed that FAHFA are regioselectively 
hydrolyzed. Finally, Kuda and coworkers38 discovered a highly unsaturated FAHFA with 
more potent anti-inflammatory activity than fully saturated 9-PAHSA. With this work in 
mind we devised a 30-member FAHFA library based on the PAHSA scaffold that would 
probe the importance of stereochemistry, regiochemistry, and saturation/unsaturation. As 
FAHFAs only contain one stereocenter, both the S and R enantiomers were selected. To 
test the influence of regiochemistry, we chose the 5-, 9-, and 13-regioisomers as they are 
the first, middle, and last regioisomers of the PAHSAs. Finally, the ester will be varied 
from palmitic acid (16:0) to oleic acid (18:1), linoleic acid (18:2), alpha-linolenic acid 
(18:3, omega-3), and gamma-linolenic acid (18:3, omega-6). The parameters of the 
FAHFA library are summarized in Table 3. 
Stereoisomers S R    2 
Regioisomers 5- 9- 13-   3 
Unsaturation PA OA LA ALA GLA 5 
      = 30 
Table 3. Summary of FAHFA SAR parameters under investigation in this chemical 
library. 
Our synthesis of 9-PAHSA provided highly enantioenriched material on multigram 
scale, however, one of the major drawbacks in the context of this chemical library was the 
ozonolysis at the end of the route. Performing such an oxidation at the end of the synthesis 
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precluded the preparation of any FAHFA analogues containing any olefins. Thus, we 
elected to end the synthesis by chemoselectively saponifying a methyl ester in the presence 
of an ester formed with a secondary alcohol. 
2.3.1 Synthesis of the 5-series 
The synthesis of the 5-series began with the protection of the primary alcohol of 
commerical 3-bromo-1-propanol 80 as the corresponding TBS ether 81. (Figure 22) 
Treatment of 81 with magnesium gave a Grignard, which added to R-(-)-epichlorohydrin 
under copper catalysis, forming chlorohydrin 82. The chlorohydrin 82 was treated with 
sodium hydroxide to give epoxide 83, which was used directly in the next step without 
purification. Addition of dodecylmagnesium bromide with catalytic copper (I) bromide 
yielded 84, which had the complete carbon skeleton of the hydroxystearic acid backbone. 
The silyl ether of 84 was deprotected with TBAF, affording diol 85. Following a procedure 
from Hansen and colleagues,67 diol 85 was converted directly to lactone 86, presumably 
through chemoselective oxidation of the primary alcohol to the corresponding aldehyde, 
formation of the six-membered lactol, then oxidation of the lactol to lactone 86. The latter 
was opened to methyl 5-hydroxystearate 87 with methanol and triethylamine in almost 
quantitative yield using conditions previously reported by Nicolau and co-workers.  
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Figure 22. Synthesis of both antipodes of methyl 5-hydroxystearate. 
Surprisingly, attempts to open the lactone with excess sodium methoxide (3 eq) in 
methanol exclusively gave 5-hydroxystearic acid, whether using ACS grade (Fisher) or 
anhydrous methanol (Alfa Aesar), commercial sodium methoxide or sodium methoxide in 
methanol prepared from freshly cut sodium metal. Furthermore, catalytic sodium 
methoxide (30 mol%) gave a disappointing mixture of unreacted lactone 86, methyl 5-
hydroxystearate 87, and 5-hydroxystearic acid.  
In order to access the other antipode of 87 without repeating the first 7 steps of the 
synthesis with S-(+)-epichlorohydrin, we attempted to invert the stereocenter of S-87 with 
the Martin and Dodge68, 69 variation of the Mitsunobu reaction. In the Organic Syntheses 
report,69 THF was used as the solvent. When replicating these conditions, we found that 
the ee% of the product had eroded markedly. By switching to benzene, the hydrocarbon 
solvent used in the original report,68 we found that the final product had cleanly inverted 
with no sign of the other enantiomer. This is a powerful reminder of the importance of 
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solvent effects on reaction outcomes. In addition to modifying the solvent, we also found 
that using tributylphosphine in lieu of triphenyl phosphine facilitated the workup. 
The 4-nitrobenzoate ester of 88 was selectively methanolized with potassium 
carbonate in methanol to afford methyl 5-hydroxystearate R-87 along with some of the 
lactone 86. Attempts to effect this same transformation with triethylamine as the base failed 
to go to completion, even when employing a large excess (21 eq) of base. 
With both enantiomers of methyl 5-hydroxystearate in hand, we attempted to 
esterify the secondary alcohol with the appropriate acid chloride and pyridine under the 
conditions employed in the synthesis of 9-PAHSA. The acid chlorides were synthesized 
from the appropriate acid with oxalyl chloride in DCM. Analysis of the crude (1H NMR) 
showed clean and complete conversion to the acid chloride. The yield of the esterification 
reaction was good for the palmitic acid chloride, but yields decreased as the degree of 
unsaturation increased, necessitating the development of an alternative process. 
The Yamaguchi esterification and the Steglich eseterification were explored. 
Neither DCC, nor EDC, nor benzoyl chloride, nor toluoyl chloride worked as well as 2,4,6-
trichlorobenzoyl chloride. Furthermore, 1.25 eq of the acid partner was optimal in our 
hands.  
Diesters 89-93 were synthesized in good yield with our optimized conditions. 
(Figures 23 and 24). Subsequent chemoselective saponification provided both enantiomers 
of 5-PAHSA 94, -OAHSA 95, -LAHSA 96, -ALAHSA 97, and -GLAHSA 98. Unlike with 
the 9- and 13-series FAHFAs, saponification of the 5-series went with more modest yield 
due to formation of the lactone 86. And 5-hydroxystearic acid. In all his elegant work on 
ring closure, Baldwin never commented on any ring greater than 7-members.66, 70-72 Even 
so, we hypothesize the methyl ester of 5-PAHSA is first saponified at the methyl ester, 
giving the corresponding carboxylate. An 8-exo-trig would engage the other ester, forming 
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a mixed anhydride. This could subsequently hydrolyze to 5-hydroxystearic acid, or the 
alkoxide could engage via a favored 6-exo-trig to form the lactone. 
 




Figure 24 Mitsunobu esterification of the R-5-series. 
 
 
Figure 25. Chemoselective saponification of the S-5-series. 
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Figure 26. Chemoselective saponification of the R-5-series. 
2.3.2 Synthesis of the 9-Series 
The synthesis the 9-series members of the FAHFA library debuted with the 
conversion of commercial 1,7-heptanediol 99 to bromoalcohol 100; refluxing the diol with 
48% HBr in toluene with a Dean-Stark trap gave the desired product in 72% yield. The 
primary alcohol of 100 was protected as the TBS ether 101. Treatment with magnesium 
gave the corresponding Grignard, which added to the unsubstituted end of R-(-)-
epichlorohydrin with the assistance of catalytic copper iodide, yielding chlorohydrin 102. 
Sodium hydroxide in dry ether converted the chlorohydrin 102 to epoxide 41. Surprisingly, 
two attempts to open the epoxide with octylmagnesium bromide and copper iodide in THF 
were unsuccessful, sparking a literature search. The epoxide opening protocol of Alam and 
coworkers73 was modified, substituting copper (I) bromide or copper (I) chloride and using 
organomagnesium bromide in place of organomagnesium chloride. This variation provided 
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the secondary alcohol 44 in good yield. The silyl ether was deprotected with TBAF, 
yielding diol 103. There are a number of reports where catalytic TEMPO preferentially 
oxidizes primary alcohols over secondary alcohols; DIAD,51 NCS,52 and trichlorocyanuric 
acid53 have all been used as the terminal oxidant. In our hands, DIAD gave the crude 
aldehyde in higher yield and purity. Two more telescoped procedures followed: Pinnick 
oxidation of the crude aldehyde and Fisher-Speier esterification gave methyl ester S-104 
in 74% yield over 3 steps.  
 
Figure 27 Synthesis of both enantiomers of methyl 9-hydroxystearate. 
As for the 5-series, methyl ester 104 was converted into both antipodes of diesters 
105-109 (Figures 28 and 29) with our optimized Yamaguchi esterification conditions. The 
methyl ester was then chemoselectively cleaved to yield the final products, S- and R-




Figure 28. Mitsunobu esterification of the S-9-series. 
 
Figure 29. Mitsunobu esterification of the R-9-series. 
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Figure 30. Chemoselective saponification of the S-9-series. 
 
Figure 31. Chemoselective saponification of the R-9-series. 
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2.3.2 Synthesis of the 13-Series 
The conditions developed for the synthesis of the 9-series of the FAHFA library 
were applied without complication to members of the 13-series. (Figure 32) Commercial 
11-bromoundecan-1-ol 115 was protected as tbs ether 116, which was converted to the 
corresponding Grignard and added to R-(-)-epichlorohydrin, yielding chlorohydrin 117. 
Formation of epoxide 118 with sodium hydroxide was followed by copper (I) catalyzed, 
regioselective epoxide opening with butylmagnesium bromide, yielding alcohol 119. Silyl 
deprotection to 120 and, oxidation and Fisher-Speier esterification gave methyl ester S-
121, whose stereocenter was inverted as before.  
 
Figure 32. Synthesis of the key methyl ester intermediates in the 13-series. 
The two antipodes of methyl 13-hydroxystearate 121 were converted to their 
diesters 122-126 (Figures 33 and 34), before the final round of saponification necessary to 
complete the 13-series (127-131, Figures 35 and 36) of the FAHFA SAR library. 
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Figure 33. Mitsunobu esterification of the S-13-series. 
 
Figure 34 Mitsunobu esterification of the R-13-series. 
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Figure 35. Chemoselective saponification of the S-13-series. 
 
Figure 36. Chemoselective saponification of the R-13-series. 
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With this 30-member library in hand, we will now be able to probe systematically 
the structure activity relationships of FAHFA for the first time. The information gained 
from these studies will show the importance of stereochemistry, regiochemistry, and 





Chapter 3: PAHSA Probes for Chemical Biology 
FAHFAs are a recently discovered family of natural product lipids with promising 
anti-diabetic and anti-inflammatory activity. Any time a novel small molecule with 
interesting in vivo and in vitro activity is discovered, two important questions should be 
asked: 1) what are the molecular targets of this small molecule and 2) how is it modified 
in cells/organisms?  
3.1 Bifunctional 9-PAHSA Probe 
To date gpr40 and gpr120 have been identified as FAHFA targets, but these 
discoveries were based on biological activity and structural similarity to known agonists. 
We wished to determine in an unbiased manner the proteins with which FAHFAs interact. 
Thankfully, The Haberkant and Cravatt labs laid the foundation for our work in this field. 
Haberkant and co-workers74 synthesized a bifunctional palmitic acid probe 136 that 
contained both a diazirine and terminal alkyne in order to investigate palmitate/protein 
interactions. The synthesis of the probe begins with addition of Grignard 133 into acid 
chloride 132, which provides 134 with the complete carbon skeleton for the probe (Figure 
37). The methyl ester and silyl protecting group were both cleaved with potassium 
hydroxide in methanol to afford 135. The ketone of 135 was converted into the diazarine 




Figure 37. Haberkant and colleagues synthesis of pacFA, a bifunctional palmitic acid 
probe. 
With the bifunctional probe in hand, they sought to determine what proteins 
interacted with their palmitic acid surrogate. The probe could form covalent adducts with 
proteins in one of two ways (Figure 38). In the absence of light, some proteins were 
acylated with the probe, giving species 137. Alternatively, irradiation with UV light caused 
the diazirine to decompose into a carbene, which rapidly formed a covalent bond with 
nearby proteins as conjugate 138. 
 
Figure 38. PacFA may form covalent bonds with protein through enzymatic acylation at 
the carboxylic acid or the carbene generated from the diazirene. 
 Acyl-alkyne 137 was then subjected to copper catalyzed cyclization with biotin-
fluorescin to form adduct 139, which was primed for visualization. The alkyne was also 
"clicked" to biotin azide, giving species 140 for proteomics. (Figure 39)  
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Figure 39. Processing of acyl adducts of pacFA. 
In another experiment, the cells incubated with the probe were irradiated with light 
to convert the diazirine of 136 into an unstable carbene that rapidly formed covalent 
attachments to nearby proteins, yielding 138. As before, the free alkyne of 138 provided a 
useful handle for the Huisgen reaction with biotin azide and fluorescin azide, permitting 
proteomic analysis and visualization, respectively, of probe-protein adducts 141 and 142. 
 
Figure 40. Processing of proteins appended to pacFA from diazirine-derived carbene. 
This method allowed Haberkant and coworkers to elucidate 185 protein targets that 
were acylated and 253 that formed adducts after irradiation with light. In addition to the 
cellular work, they also found that their probe was effective in vivo with model organism 
C. elegans. 
The Cravatt lab75 similarly used a bifunctional cholesterol mimic 149 to investigate 
cholesterol-protein interactions. (Figure 41) Hulce and co-workers start with a 
chemoselective potassium chromate mediated oxidation of the secondary alcohol at C6 of 
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hyodeoxycholic acid 143 to the corresponding ketone 144. Treatment of 144 with methanol 
and hydrochloric acid converts the carboxylic acid to the corresponding methyl ester, while 
also epimerizing the proton at C5 to give ester 145. The secondary alcohol of 145 was 
converted to the corresponding mesylate 146. Substitution of mesylate 146 with acetate 
went cleanly with inversion of stereochemistry at C3, yielding 147. Both of the esters of 
147 were saponified with lithium hydroxide, revealing the secondary alcohol and 
carboxylic acid of 148. The synthesis of bifunctional probe 149 ends with conversion of 
the ketone at C6 to a diazirine and Steglich esterification of 5-hexyn-1-ol to the carboxylic 
acid to append the requisite alkyne. 
 
Figure 41. The Cravatt synthesis of a bifunctional diazirine-alkyne cholesterol probe from 
hyodeoxycholic acid. 
The probe 149 was then incubated with HeLa cells and irradiated with 365 nm UV 
light to generate a carbene, which formed covalent adduct 150 with nearby proteins (Figure 
42). Similar to the Haberkant report, the free alkyne was then “clicked” to functionalized 
 52 
azides for visualization and proteomics. For the visualization studies, the Cravatt lab used 
a rhodamide functionalized azide in place of the fluorescin azide selected by the Haberkant 
lab. With their cholesterol probe, Hulce et al identified 265 likely cholesterol-protein 
targets. Some of these protein interactions were known, validating the method, while other 
proteins had theretofore unknown interactions with cholesterol.  
 
Figure 42. Cravatt’s covalent capture of proteins with a bifunctional cholesterol and 
subsequent processing. 
Taking our cues from these two outstanding examples of chemical biology, we 
designed our own bifunctional probes 153 based on 9-PAHSA (Figure 43), the most well 
studied of the FAHFAs. As in the above examples, our probe contains a photoreactive 
diazirine and a terminal alkyne. In light of what we have learned about FAHFA hydrolysis, 
we thought it essential to place the diazirine and alkyne moieties on different parts of the 
molecule, so that only proteins that interact with intact FAHFA would be pulled down. The 
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diazirine was placed on the fatty acid portion and the alkyne positioned on the HFA for 
ease of synthesis. 
 
Figure 43. 9-PAHSA inspired bifunctional diazirine-alkyne probe. 
The synthesis began with copper catalyzed addition of Grignard 154 to epoxide 41, 
which was also used to synthesize the 9-series members of the FAHFA library. (Figure 44) 
The two silyl protecting groups were deprotected with TBAF, yielding diol 156. 
Gratifyingly, the previously developed chemoselective oxidation, Pinnick oxidation, and 
Fisher-Speier esterification were effective on this substrate, giving methyl ester S-159. The 
antipode R-159 was again synthesized using the Martin-Dodge variant of the Mitsunobu 
reaction, followed by chemoselective ester cleavage.  
 
Figure 44. Synthesis of the alkyne-hydroxyfatty acid backbone of the 9-PAHSA probe. 
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The diazirine moiety was synthesized from commercially available acid chloride 
160. (Figure 45) Addition of undecylmagnesium bromide under copper catalysis to acid 
chloride 160 gave keto-ester 161, which was previously synthesized with toxic cadmium.76 
Saponification with potassium hydroxide gave known keto-acid 162.77 The ketone of 162 
was converted to diazirine 163 by the usual sequence. More recent methods using liquid 
ammonia were ineffective in our hands. 
 
Figure 45. Synthesis of the diazirine moiety of the 9-PAHSA probe. 
Diazirine-acid 163 was then appended to the secondary alcohol of S-159 via 
Steglich esterification with EDCI, giving the penultimate product S-160. Chemoselective 
cleavage of the methyl ester with lithium hydroxide in THF gave the desired bifunctional 




Figure 46. Endgame of the 9-PAHSA diazirine-alkyne probe. 
Experiments are presently underway to determine the proteins with which 9-
PAHSA derived probe S/R-153 interacts. As the structure is similar to the natural product, 
the probe should allow us to determine in an unbiased manner the targets of 9-PAHSA, 
while also confirming the known interactions with gpr40 and gpr120. The results will be 
reported in due course. 
3.2 COBALT CATCH-AND-RELEASE OF ALKYNYL-9-PAHSA 
 While the bifunctional probe 153 will be a useful tool to determine the proteins 
with which 9-PAHSA interacts, it will be of limited value in the determination of the 
cellular and organismal metabolism of 9-PAHSA and 9-HSA. The data suggests that 
FAHFAs are enzymatically hydrolyzed to form HFAs and that HFAs are enzymatically 
acylated to form FAHFAs. It is easy to imagine many other possibilities, such as extension, 
beta oxidation, acylation, elimination of the secondary alcohol. How can we determine in 
an impartial manner the ways in which cells/organisms metabolize 9-PAHSA and 9-HSA?   
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 Luckily, the labs of Brown and Turner have developed an ingenious solution to this 
problem. They found it was possible to “catch-and-release” alkynyl fatty acids that were 
incubated with cells. (Figure 47) First, lipids, including alkynyl lipids 161, were extracted 
from the cell medium, then treated with Co2(CO)8, forming organocobalt species 162. A 
silica supported phosphine resin 163 then displaced one of the carbonyl ligands from 163, 
forming complex 164. The solid support was then washed, removing compounds that did 
not contain any alkynes. Finally, complex 164 was treated with iron (III) nitrate, restoring 
alkyne 165.  
 
Figure 47. Cobalt “Catch-and-Release” approach to enriching samples. 
 Brown and Turner have validated this method with alkynyl palmitic acid surrogate 
166. (Figure 48) Probe 166 was incubated with RAW264.7 cells and, after lipid extraction 
and cobalt catch-and-release, analysis revealed that the majority of 166 was incorporated 
into phosphatidylcholine at position 1 167, position 2 168, or both 1 and 2 169. 
Furthermore, 166 was also elongated by 2 carbons, yielding alkynyl stearic acid 170. 
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Figure 48. RAW264.7 cells incorporate palmitic acid surrogate into phosphatidylcholine 
lipids and elongate it by 2 carbons. 
 This clever work by Brown and Turner shows that, even with terminal alkyne in 
place, cells process fatty acids comparably to their native counterparts. With this in mind 
we have prepared both antipodes of a 9-HSA alkynyl derivative 158. (Figure 49) 
Saponification of 159 with lithium hydroxide gave the products in good yield. 
 
Figure 49. Synthesis of both enantiomers of 9-hydroxystearic acid probe for cobalt catch-
and-release. 
In addition, we also synthesized alkynal 9-PAHSA in order to investigate its 
metabolism. The secondary alcohol of 159 was acylated with palmitoyl chloride, yielding 
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diester 171, which was chemoselectively saponified with lithium hydroxide to the desired 
alkyne derivative 172. 
 
Figure 50. Synthesis of alkynyl 9-PAHSA for cobalt catch-and-release. 
 To recapitulate, we have synthesized both a bifunctional diazirine-alkyne derivative 
of 9-PAHSA and an alkynyl variant of 9-PAHSA. The former will allow us to determine 
in an unbiased manner the small molecule-protein interactions in which 9-PAHSA 
participates; the latter will provide an unprejudiced view of the small molecule 
modification that 9-PAHSA experiences. The results of this experimentation will be 




All reactions were performed in flame- or oven-dried glassware sealed with rubber 
septa and under nitrogen atmosphere, unless otherwise indicated.  Air- and/or moisture-
sensitive liquids or solutions were transferred by cannula or syringe.  Organic solutions 
were concentrated by rotary evaporator at 30 millibar with the water bath heated to not 
more than 40°C, unless specified otherwise.  Tetrahydrofuran (THF), diethyl ether (Et2O), 
and dichloromethane (DCM) were purified with a Pure-Solve MD-5 Solvent Purification 
System (Innovative Technology).  Thin-layer chromatography (TLC) was performed using 
0.2 mm commercial silica gel plates (silica gel 60, F254, EMD Chemicals) and visualized 
with a UV lamp (short and long wave) and/or aqueous potassium permanganate (KMnO4) 
stain.  Optical rotations were measured on a JASCO P-2000 polarimeter.  Melting points 
were measured with a MEL-TEMP apparatus without correction.  Nuclear Magnetic 
Resonance (NMR) spectra were recorded on a Varian 600 MHz (1H at 600 MHz, 13C at 
151 MHz).  All spectra were taken in CDCl3 with shifts reported in parts per million (ppm) 
referenced to protium or carbon of the solvent (7.26 or 77.16, respectively).  Coupling 
constants are reported in Hertz (Hz).  Data for 1H-NMR are reported as follows: chemical 
shift (ppm, reference to protium; s = single, d = doublet, t = triplet, q = quartet, dd = doublet 
of doublets, ddd = doublet of doublet of doublets, m = multiplet, coupling constant (Hz), 
and integration).  High Resolution Mass Spectra (HRMS) were acquired on an Agilent 
6230 High Resolution time-of-flight mass spectrometer and reported as m/z for the 
molecular ion [M+Na]+, [M+H]+, [M-H]+, or [M-Cl]+.    
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Synthesis of Racemic 5- and 9-PAHSA 
 
nonadec-1-en-6-ol 25 
A 250 mL round-bottom flask equipped with stir bar was charged sequentially with 
tetradecanol (21.44 g, 100 mmol, 1 eq), DCM (100 mL, 1 M), TEMPO (1.56 g, 10.0 mmol, 
0.1 eq), and DAIB (35.4 g, 110 mmol, 1.1 eq), giving a clear, orange solution. The reaction 
was monitored by TLC. Upon completion the reaction was quenched with sat aq sodium 
thiosulfate (100 mL) and DI water (50 mL), extracted with ethyl acetate (100 mL x 3). 
Organics were combined and washed with sat aq sodium bicarbonate (50 mL x 3) and brine 
(50 mL), dried (sodium sulfate), filtered, concentrated, and used in the next step without 
further purification. 
A 500 mL dry round-bottom flask under nitrogen atmosphere and equipped with 
stir bar was charged with tetradecanal (100 mmol, 1 eq) and dissolved in dry THF (200 
mL, 0.5M).  Stirring was initiated, giving a clear solution. The reaction vessel was cooled 
in an ice water bath before adding a solution pent-4-enylmagnesium bromide 24  (228 mL, 
0.527 M, 120 mmol, 1.2 eq) dropwise via syringe pump over 60 minutes. 
The Grignard 24 was prepared as follows: a 500 mL round-bottom flask was 
equipped with stir bar and magnesium turnings (18.23 g, 750 mmol, 3.75 eq). The reaction 
vessel was flame-dried under vacuum, cooled to ambient temperature, flushed with 
nitrogen, and sealed with a rubber septum.  Dry THF (200 mL, 1 M) was added via syringe.  
Stirring was initiated, giving a heterogeneous mixture of solvent and turnings.  A solution 
of DIBAL in toluene (6.25 mL, 1.2 M, 7.50 mmol, 0.0375 eq) was added by syringe and 
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the reaction was aged for 5 min.  The reaction vessel was then warmed to 35°C in an oil 
bath before adding dropwise via syringe pump over 200 minutes 5-bromo-1-pentene (23.7 
mL, 200 mmol, 1 eq). After addition was complete, the reaction was warmed to 50°C, then 
cooled to ambient temperature. The Grignard was titrated according to the method of 
Paquette (Synthetic Communication. 1994, 24, 2503-2506) and the concentration was 
0.527 M. 
The reaction was allowed to warm to ambient temperature overnight, quenched 
with saturate aqueous ammonium chloride (100 mL). The mixture was transferred to a 
separatory funnel and extracted with a mixture of ethyl ether:hexanes (50:50, 200 mL x 3).  
Combined organics were washed with brine (100 mL), dried (sodium sulfate), filtered, and 
concentrated to give a crude solid.  The residue was purified by silica gel column 
chromatography, eluting with hexanes:EtOAc (95:5 to 90:10) to yield alcohol 25 (17.52 g, 
62%) as a white solid. 
 
Rf = 0.35 (silica gel, 90:10 hexanes:EtOAc, KMnO4); MP (°C): 42-43; 1H-NMR 
(600 MHz, CDCl3): δ 5.81 (m, 1H), 5.04 – 4.98 (m, 1H), 4.98 – 4.93 (m, 1H), 3.59 (s, 1H), 
2.12 – 2.02 (m, 2H), 1.59 – 1.21 (m, 29H), 0.88 (t, J = 7.0 Hz, 3H); 13C-NMR (151 MHz, 
CDCl3): δ 138.91, 114.71, 72.01, 37.69, 37.03, 33.89, 32.07, 29.85, 29.84, 29.82, 29.81, 
29.80, 29.78, 29.77, 29.51, 25.80, 25.08, 22.84, 14.26; IR (film, cm-1): 911, 1467, 2849, 




A dry 1000 mL round-bottom flask equipped with stir, under nitrogen atmosphere, 
and sealed with a rubber septum was charged with alcohol 25 (17.52 g, 62.0 mmol, 1 eq) 
and dry dichloromethane (374 mL, 0.17 M).  Stirring was initiated, giving a clear solution.  
Dry pyridine (25.1 mL, 310 mmol, 5 eq) was added dropwise via syringe.  The reaction 
vessel was submerged in an ice water bath and aged 30 minutes.  Palmitoyl chloride (20.7 
mL, 68.2 mmol, 1.1 eq) was added dropwise via syringe.  The reaction was allowed to 
warm to ambient temperature and stirred overnight.  The reaction was quenched with 
deionized water (100 mL) and stirred vigorously for 30 minutes.  The biphasic mixture was 
transferred to a separatory funnel.  The layers were partitioned and separated.  The organic 
layer was saved while the aqueous layer was extracted with dichloromethane (150 mL x 
2).  Organics were combined and washed with 0.5 M aqueous hydrochloric acid (100 mL), 
saturate aqueous sodium bicarbonate (100 mL), and brine (100 mL), dried (sodium sulfate), 
filtered, and concentrated.  The crude product was purified by silica column 
chromatography, eluting with hexanes:EtOAc (100:0 to 95:5) to give 26 (29.1 g, 90%) as 
a clear oil. 
 
Clear oil.  Yield = 90%; Rf = 0.52 (silica gel, 95:5 hexanes:EtOAc, KMnO4); 1H-
NMR (600 MHz, CDCl3): 1H NMR (600 MHz, CDCl3) δ 5.78 (m, 1H), 5.00 (dd, J = 17.1, 
1.6 Hz, 1H), 4.95 (dd, J = 10.1, 0.7 Hz, 1H), 4.92 – 4.84 (m, 1H), 2.28 (t, J = 7.5 Hz, 2H), 
2.07 – 2.00 (m, 2H), 1.65 – 1.57 (m, 2H), 1.57 – 1.21 (m, 52H), 0.88 (t, J = 7.0 Hz, 6H); 
13C-NMR (151 MHz, CDCl3): δ 173.84, 138.67, 114.82, 73.99, 34.88, 34.32, 33.73, 
33.71, 32.08, 29.85, 29.84, 29.83, 29.81, 29.78, 29.74, 29.70, 29.68, 29.66, 29.52, 29.46, 
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29.35, 25.46, 25.34, 24.74, 22.84, 14.26; IR (film, cm-1): 1466, 1735, 2853, 2924; HRMS 





4-methylmorpholine N-oxide monohydrate (20.3 g, 150 mmol, 3 eq) was 
dehydrated by heating at 90°C under high vacuum overnight.  Following the ozonolysis 
conditions of Drussault, a 500 mL round-bottom flask was charged with olefin X (26.0 g, 
50 mmol, 1 eq), the anhydrous 4-methyl N-oxide prepared above, and dry DCM (333 mL, 
0.15M).  Stirring was initiated, affording a clear solution.  The reaction vessel was 
submerged in an ice-acetone bath and cooled to approximately -10°C for 15 minutes before 
bubbling in a mixture of ozone/oxygen.  Conversion was complete within 15 minutes.  The 
ozone generator was turned off and oxygen was bubbled through the solution for an 
additional 5 minutes.  The reaction vessel was allowed to warm to ambient temperature 
and aged for 1 hour.  The reaction was concentrated and the residue was dissolved in ethyl 
acetate (300 mL) and washed with water (100 mL) and brine (50 mL x 2), dried (sodium 
sulfate), filtered, and concentrated.  The crude material was used in the next step without 
further purification. 
A 250 mL round-bottom flask equipped with stir bar and addition funnel was 
charged with the crude material above and dissolved in 2-methyl-2-butene (53 mL, 500 
mmol, 10 eq) and tert-butanol (250 mL, 0.2 M).  Stirring was initiated, affording a clear 
solution.  The reaction vessel was cooled in an ice-water bath for 30 minutes before adding 
an aqueous solution of sodium phosphate monobasic monohydrate (27.6 g, 200 mmol, 4 
eq) and sodium chlorite (technical grade, 80%, 22.6 g, 200 mmol, 4 eq) in deionized water 
(125 mL) dropwise via addition funnel.  The reaction was allowed to warm to ambient 
temperature and stirred overnight.   
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Peroxide test strips revealed the presence of peroxides.  After adding an aqueous 
solution of sodium bisulfite (31.2 g, 300 mmol, 6 eq) in deionized water (125 mL) dropwise 
via addition funnel and aging 30 minutes, peroxides were absent.  2-methyl-2-butene and 
tert-butanol were removed by rotavap with water bath at 50°C.  The residual aqueous layer 
was extracted with hexanes:ethyl acetate (50:50, 100 mL x 3).  Combined organics were 
washed with brine (100 mL), dried (sodium sulfate), filtered, and concentrated.  The crude 
product was purified by silica column chromatography, eluting with hexanes:EtOAc 
(90:10 to 70:30) to yield X (25.3 g. 94%) as a white solid. 
 
Rf = 0.29 (silica gel, 80:20 hexanes:EtOAc, KMnO4); MP: (°C) 34; 1H-NMR (600 
MHz, CDCl3): δ 4.89 – 4.83 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 
1.65 – 1.58 (m, 4H), 1.50 (m, J = 4.8 Hz, 4H), 1.27 (m, J = 22.8 Hz, 46H), 0.88 (t, J = 6.8 
Hz, 6H); 13C-NMR (151 MHz, CDCl3): δ 179.05, 173.91, 74.17, 34.90, 34.31, 34.28, 
33.97, 32.08, 32.05, 29.85, 29.82, 29.81, 29.78, 29.71, 29.69, 29.67, 29.51, 29.46, 29.46, 
29.35, 29.27, 29.12, 25.47, 25.40, 25.34, 24.78, 22.84, 22.83, 14.26, 14.25; IR (film, cm-
1): 1466, 1635, 1711, 1733, 2854, 2925, 3427; HRMS (ESI) calc. for C34H66O4Na 





A 250 mL round-bottom flask equipped with stir bar was charged sequentially with 
decanol (19.07 mL, 100 mmol, 1 eq), DCM (100 mL, 1 M), TEMPO (1.56 g, 10.0 mmol, 
0.1 eq), and DAIB (35.4 g, 110 mmol, 1.1 eq), giving a clear, orange solution. The reaction 
was monitored by TLC. Upon completion the reaction was quenched with sat aq sodium 
thiosulfate (100 mL) and DI water (50 mL), extracted with ethyl acetate (100 mL x 3). 
Organics were combined and washed with sat aq sodium bicarbonate (50 mL x 3) and brine 
(50 mL), dried (sodium sulfate), filtered, concentrated, and used in the next step without 
further purification. 
A 500 mL dry round-bottom flask under nitrogen atmosphere and equipped with 
stir bar was charged with decanal (100 mmol, 1 eq) and dissolved in dry THF (200 mL, 
0.5M).  Stirring was initiated, giving a clear solution. The reaction vessel was cooled in an 
ice water bath before adding a solution non-8-enylmagnesium bromide X (239 mL, 0.502 
M, 120 mmol, 1.2 eq) dropwise via syringe pump over 60 minutes. 
The Grignard 70 was prepared as follows: a 500 mL round-bottom flask was 
equipped with stir bar and magnesium turnings (18.23 g, 750 mmol, 3.75 eq). The reaction 
vessel was flame-dried under vacuum, cooled to ambient temperature, flushed with 
nitrogen, and sealed with a rubber septum.  Dry THF (200 mL, 1 M) was added via syringe.  
Stirring was initiated, giving a heterogeneous mixture of solvent and turnings.  A solution 
of DIBAL in toluene (6.25 mL, 1.2 M, 7.50 mmol, 0.0375 eq) was added by syringe and 
the reaction was aged for 5 min.  The reaction vessel was then warmed to 35°C in an oil 
bath before adding dropwise via syringe pump over 200 minutes 9-bromo-1-nonene (37.1 
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mL, 200 mmol, 1 eq). After addition was complete, the reaction was warmed to 50°C, then 
cooled to ambient temperature. The Grignard was titrated according to the method of 
Paquette (Synthetic Communication. 1994, 24, 2503-2506) and the concentration was 
0.502 M. 
The reaction was allowed to warm to ambient temperature overnight, quenched 
with saturate aqueous ammonium chloride (100 mL). The mixture was transferred to a 
separatory funnel and extracted with a mixture of ethyl ether:hexanes (50:50, 200 mL x 3).  
Combined organics were washed with brine (100 mL), dried (sodium sulfate), filtered, and 
concentrated to give a crude solid.  The residue was purified by silica gel column 
chromatography, eluting with hexanes:EtOAc (95:5 to 90:10) to yield alcohol X (18.65 g, 
66%) as a white solid. 
 
nonadec-1-en-10-ol 71 
Rf = 0.41 (silica gel, 90:10 hexanes:EtOAc, KMnO4); MP (°C): 51-52; 1H-NMR 
(600 MHz, CDCl3) δ 5.80 (m, 1H), 4.98 (dd, J = 17.1, 1.6 Hz, 1H), 4.92 (d, J = 10.2 Hz, 
1H), 3.59 – 3.54 (m, 1H), 2.03 (q, J = 7.1 Hz, 2H), 1.48 – 1.20 (m, 29H), 0.87 (t, J = 7.0 
Hz, 3H); 13C-NMR (151 MHz, CDCl3): δ 139.30, 114.25, 72.11, 37.64, 37.61, 33.92, 
32.03, 29.86, 29.79, 29.78, 29.72, 29.60, 29.46, 29.22, 29.05, 25.80, 25.78, 22.81, 14.23; 
IR (film, cm-1):  650, 735, 909, 994, 1466, 2854, 2926, 3373; HRMS (APCI) calc. for 






A dry 1000 mL round-bottom flask equipped with stir, under nitrogen atmosphere, 
and sealed with a rubber septum was charged with alcohol X (18.21 g, 64.5 mmol, 1 eq) 
and dry dichloromethane (388 mL, 0.17 M).  Stirring was initiated, giving a clear solution.  
Dry pyridine (26.1 mL, 322 mmol, 5 eq) was added dropwise via syringe.  The reaction 
vessel was submerged in an ice water bath and aged 30 minutes.  Palmitoyl chloride (21.5 
mL, 70.9 mmol, 1.1 eq) was added dropwise via syringe.  The reaction was allowed to 
warm to ambient temperature and stirred overnight.  The reaction was quenched with 
deionized water (100 mL) and stirred vigorously for 30 minutes.  The biphasic mixture was 
transferred to a separatory funnel.  The layers were partitioned and separated.  The organic 
layer was saved while the aqueous layer was extracted with dichloromethane (150 mL x 
2).  Organics were combined and washed with 0.5 M aqueous hydrochloric acid (100 mL), 
saturate aqueous sodium bicarbonate (100 mL), and brine (100 mL), dried (sodium sulfate), 
filtered, and concentrated.  The crude product was purified by silica column 
chromatography, eluting with hexanes:EtOAc (100:0 to 95:5) to give X (31.2 g, 93%) as a 
clear oil. 
 
nonadec-1-en-10-yl palmitate 5 
Rf = 0.58 (silica gel, 95:5 hexanes:EtOAc, KMnO4); 1H-NMR (600 MHz, CDCl3): 
δ 5.80 (m, 1H), 4.98 (dd, J = 17.1, 1.4 Hz, 1H), 4.92 (d, J = 10.2 Hz, 1H), 4.89 – 4.84 (m, 
1H), 2.27 (t, J = 7.5 Hz, 2H), 2.03 (q, J = 7.1 Hz, 2H), 1.65 – 1.58 (m, 2H), 1.50 (m, J = 
5.0 Hz, 4H), 1.43 – 1.20 (m, 48H), 0.88 (t, J = 7.0 Hz, 6H); 13C-NMR (151 MHz, CDCl3): 
δ 173.80, 139.27, 114.27, 74.16, 34.89, 34.32, 34.31, 33.93, 32.08, 32.05, 29.85, 29.84, 
29.82, 29.81, 29.78, 29.71, 29.69, 29.67, 29.62, 29.53, 29.51, 29.47, 29.35, 29.19, 29.05, 
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25.47, 25.45, 25.34, 22.84, 22.83, 14.25, 14.24; IR (film, cm-1) 909, 1176, 1466, 1734, 





4-methylmorpholine N-oxide monohydrate (20.3 g, 150 mmol, 3 eq) was 
dehydrated by heating at 90°C under high vacuum overnight.  Following the ozonolysis 
conditions of Drussault, a 500 mL round-bottom flask was charged with olefin X (26.0 g, 
50 mmol, 1 eq), the anhydrous 4-methyl N-oxide prepared above, and dry DCM (333 mL, 
0.15M).  Stirring was initiated, affording a clear solution.  The reaction vessel was 
submerged in an ice-acetone bath and cooled to approximately -10°C for 15 minutes before 
bubbling in a mixture of ozone/oxygen.  Conversion was complete within 15 minutes.  The 
ozone generator was turned off and oxygen was bubbled through the solution for an 
additional 5 minutes.  The reaction vessel was allowed to warm to ambient temperature 
and aged for 1 hour.  The reaction was concentrated and the residue was dissolved in ethyl 
acetate (300 mL) and washed with water (100 mL) and brine (50 mL x 2), dried (sodium 
sulfate), filtered, and concentrated.  The crude material was used in the next step without 
further purification. 
A 250 mL round-bottom flask equipped with stir bar and addition funnel was 
charged with the crude material above and dissolved in 2-methyl-2-butene (53 mL, 500 
mmol, 10 eq) and tert-butanol (250 mL, 0.2 M).  Stirring was initiated, affording a clear 
solution.  The reaction vessel was cooled in an ice-water bath for 30 minutes before adding 
an aqueous solution of sodium phosphate monobasic monohydrate (27.6 g, 200 mmol, 4 
eq) and sodium chlorite (technical grade, 80%, 22.6 g, 200 mmol, 4 eq) in deionized water 
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(125 mL) dropwise via addition funnel.  The reaction was allowed to warm to ambient 
temperature and stirred overnight.   
Peroxide test strips revealed the presence of peroxides.  After adding an aqueous 
solution of sodium bisulfite (31.2 g, 300 mmol, 6 eq) in deionized water (125 mL) dropwise 
via addition funnel and aging 30 minutes, peroxides were absent.  2-methyl-2-butene and 
tert-butanol were removed by rotavap with water bath at 50°C.  The residual aqueous layer 
was extracted with hexanes:ethyl acetate (50:50, 100 mL x 3).  Combined organics were 
washed with brine (100 mL), dried (sodium sulfate), filtered, and concentrated.  The crude 
product was purified by silica column chromatography, eluting with hexanes:EtOAc 
(90:10 to 70:30) to yield X (25.6 g. 95%) as a white solid. 
9-PAHSA 6 
Rf = 0.29 (silica gel, 80:20 hexanes:EtOAc, KMnO4); MP: (°C) 34; 1H-NMR (600 
MHz, CDCl3): δ 4.89 – 4.83 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 
1.65 – 1.58 (m, 4H), 1.50 (m, J = 4.8 Hz, 4H), 1.27 (m, J = 22.8 Hz, 46H), 0.88 (t, J = 6.8 
Hz, 6H); 13C-NMR (151 MHz, CDCl3): δ 179.05, 173.91, 74.17, 34.90, 34.31, 34.28, 
33.97, 32.08, 32.05, 29.85, 29.82, 29.81, 29.78, 29.71, 29.69, 29.67, 29.51, 29.46, 29.46, 
29.35, 29.27, 29.12, 25.47, 25.40, 25.34, 24.78, 22.84, 22.83, 14.26, 14.25; IR (film, cm-
1): 1466, 1635, 1711, 1733, 2854, 2925, 3427; HRMS (ESI) calc. for C34H66O4Na 





Synthesis of Enantiopure 9-PAHSA and 9-HAS 
 
A  250 mL round-bottom flask equipped with stir bar and charged with magnesium 
turnings (2.96 g, 122 mmol, 3.75 eq) was flame dried under vacuum, cooled to ambient 
temperature, flushed with nitrogen, and sealed with a rubber septum.  Dry THF (66 mL, 
2/3 total volume) was added by syringe.  Stirring was initiated, affording a heterogeneous 
mixture of clear solvent and metal turnings.  A solution of DIBAL in toluene (0.27 mL, 1.2 
M, 0.32 mmol, 0.01 eq) was added via syringe to activate the magnesium turnings.  The 
reaction vessel was submerged in an oil bath, warmed to 35°C, and aged for 5 minutes 
before adding  8-bromo-1-octene (8.16 mL, 48.6 mmol, 1.5 eq)  dropwise over 30 minutes 
by syringe pump.  The reaction turned increasingly brown over the course of addition and 
the temperature rose to 41°C.  After addition was complete, the vessel was warmed to 50°C 
before being allowed to cool to ambient temperature.  The reaction was stirred for an 
additional 2 hours.  A second 250 mL round-bottom flask equipped with stir bar and 
charged with copper (I) iodide (0.62 g, 3.24 mmol, 0.10 eq) was flame dried under vacuum, 
cooled to ambient temperature, flushed with nitrogen, sealed with a rubber septum, and 
maintained under a nitrogen atmosphere.  Dry THF (33 mL, 1/3 total volume) and S-(-)-
epichlorohydrin 4 (2.54 mL, 32.4 mmol, 1 eq) were added by syringe, giving a white, 
opaque mixture.  The reaction vessel was submerged in a dry ice-acetone bath and cooled 
for 15 minutes.  The Grignard reagent prepared above was drawn up in a syringe and added 
dropwise via syringe pump over 1 hour to the cooled mixture of S-(-)-epichlorohydrin 4.  
The reaction was allowed to warm to ambient temperature overnight and the color changed 
to a deep, dark blue.  The reaction was carefully quenched with 100 mL saturated aqueous 
ammonium chloride.  The mixture was stirred vigorously until the color changed to a 
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brilliant, royal blue.  The mixture was transferred to a separatory funnel and extracted with 
a mixture of ethyl ether:hexanes (50:50, 50 mL x 3).  Combined organics were washed 
with saturated aqueous ammonium chloride (50 mL x 2), brine (50 mL), dried (sodium 
sulfate), filtered, and concentrated to give a crude, slightly yellow oil.  The residue was 
purified by silica gel column chromatography, eluting with hexanes:EtOAc (95:5 to 90:10) 
to afford S-5 (6.11 g, 92%) as a clear oil. 
 
S-1-chloroundec-10-en-2-ol 5 
Rf = 0.29 (silica gel, 90:10 hexanes:EtOAc, KMnO4); 1H-NMR (600 MHz, 
CDCl3): δ 5.81 (m, 1H), 5.02 – 4.96 (m, 1H), 4.95 – 4.90 (m, 1H), 3.83 – 3.77 (m, 1H), 
3.63 (dd, J = 11.1, 3.2 Hz, 1H), 3.47 (dd, J = 11.1, 7.2 Hz, 1H), 2.13 (d, J = 4.9 Hz, 1H), 
2.04 (q, J = 14.4, 7.0 Hz, 2H), 1.57 – 1.26 (m, 13H); 13C-NMR (151 MHz, CDCl3): δ 
139.30, 114.33, 71.61, 50.76, 34.37, 33.91, 29.58, 29.47, 29.15, 29.02, 25.65; IR (film, cm-






A 100 mL round-bottom flask equipped with an egg-shaped stir bar was charged 
with chlorohydrin 5 (5.61 g, 27.4 mmol, 1 eq) and dissolved in dry ether (55 mL, 0.5M).  
Stirring was initiated, giving a clear solution.  Freshly crushed sodium hydroxide (6.58 g, 
164 mmol, 6 eq) was added in one portion, affording a heterogeneous mixture.  The 
reaction was stirred vigorously (1200 rpm) and monitored by aliquot 1H-NMR.  
Conversion was complete within 3 hours.  The mixture was vacuum filtered into a dry flask 
containing 4Å mole sieves, rinsing the filter cake with dry ether (25 mL x 3).  The vessel 
was sealed with a rubber septum and spurged with nitrogen.  After aging over sieves for 3 
hours, crude epoxide 6 was used without purification. 
A 500 mL round-bottom flask charged with magnesium turnings (4.01 g, 165 
mmol, 1 eq) and equipped with a stir bar and reflux condenser.  The ensemble was flame 
dried under vacuum, cooled to ambient temperature, flushed with nitrogen, sealed with a 
rubber septum, and maintained under a nitrogen atmosphere.  Dry ether (82.5 mL, 1/2 total 
volume) was added via syringe.  Stirring was initiated, giving a heterogeneous mixture of 
solvent and turnings.  A solution of DIBAL in toluene (1.38 mL, 1.2 M, 1.65 mmol, 0.01 
eq) was added by syringe and the reaction was aged for 5 min.  A clear solution of 1-
chlorooctane (28.0 mL, 165 mmol, 1 eq) in dry ether (82.5 mL, 1/2 total volume) was added 
dropwise and the reaction was heated to reflux for 3 hours.  The reaction yellowed slightly 
over the course of the reflux and grew increasingly opaque.  Most of the magnesium 
turnings were consumed.  The reaction was allowed to cool to ambient temperature.  
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Stirring was arrested and the supernatant solution of 1-octylmagnesium chloride was 
titrated as 0.52 M using the method of Love and Jones. 
A 500 mL round-bottom flask equipped with stir bar and charged with copper (I) 
iodide (0.522 g, 2.75 mmol, 0.1 eq) was flame dried under vacuum, cooled to ambient 
temperature, flushed with nitrogen, and sealed with a rubber septum.  The ethereal solution 
of epoxide 5 was vacuum filtered into the reaction vessel to remove the molecular sieves.  
Stirring was initiated, affording an opaque mixture.  A dry addition funnel was attached 
and the reaction was cooled in a dry ice-acetone bath for 30 minutes.  The ethereal solution 
of 1-octylmagnesium chloride (79 mL, 0.52 M, 41.3 mmol, 1.5 eq) prepared above was 
transferred via cannula to the addition funnel and added dropwise over 1 hour.  The reaction 
mixture was allowed to warm to ambient temperature overnight and the color changed to 
a deep, dark blue.  The reaction was carefully quenched with 200 mL saturated aqueous 
ammonium chloride.  The mixture was stirred vigorously until the color changed to a 
brilliant, royal blue.  The mixture was transferred to a separatory funnel and extracted with 
a mixture of ethyl ether:hexanes (50:50, 100 mL x 3).  Combined organics were washed 
with saturated aqueous ammonium chloride (50 mL x 2), brine (50 mL), dried (sodium 
sulfate), filtered, and concentrated to give a crude solid.  The residue was purified by silica 
gel column chromatography, eluting with hexanes:EtOAc (95:5 to 90:10) to yield R-7 (5.45 
g, 70%) as a white solid. 
 
R-nonadec-1-en-10-ol 7 
Rf = 0.41 (silica gel, 90:10 hexanes:EtOAc, KMnO4); MP (°C): 51-52; 1H-NMR 
(600 MHz, CDCl3) δ 5.80 (m, 1H), 4.98 (dd, J = 17.1, 1.6 Hz, 1H), 4.92 (d, J = 10.2 Hz, 
1H), 3.59 – 3.54 (m, 1H), 2.03 (q, J = 7.1 Hz, 2H), 1.48 – 1.20 (m, 29H), 0.87 (t, J = 7.0 
Hz, 3H); 13C-NMR (151 MHz, CDCl3): δ 139.30, 114.25, 72.11, 37.64, 37.61, 33.92, 
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32.03, 29.86, 29.79, 29.78, 29.72, 29.60, 29.46, 29.22, 29.05, 25.80, 25.78, 22.81, 14.23; 







A dry 250 mL round-bottom flask equipped with stir bar, under nitrogen 
atmosphere, and sealed with a rubber septum was charged with alcohol 7 (4.45 g, 15.8 
mmol, 1 eq) and dry dichloromethane (95 mL).  Stirring was initiated, giving a clear 
solution.  Dry pyridine (6.37 mL, 79 mmol, 5 eq) was added dropwise via syringe.  The 
reaction vessel was submerged in an ice water bath and aged 15 minutes.  Palmitoyl 
chloride (5.26 mL, 17.3 mmol, 1.1 eq) was added dropwise via syringe.  The reaction was 
allowed to warm to ambient temperature and stirred overnight.  The reaction was quenched 
with deionized water (100 mL) and stirred vigorously for 30 minutes.  The biphasic mixture 
was transferred to a separatory funnel.  The layers were partitioned and separated.  The 
organic layer was saved while the aqueous layer was extracted with dichloromethane (150 
mL x 2).  Organics were combined and washed with 0.5 M aqueous hydrochloric acid (100 
mL), saturate aqueous sodium bicarbonate (100 mL), and brine (100 mL), dried (sodium 
sulfate), filtered, and concentrated.  The crude product was purified by silica column 
chromatography, eluting with hexanes:EtOAc (100:0 to 95:5) to give 8 (7.46 g, 91%) as a 
yellow oil. 
 
R-nonadec-1-en-10-yl palmitate 8 
Rf = 0.58 (silica gel, 95:5 hexanes:EtOAc, KMnO4); 1H-NMR (600 MHz, CDCl3): 
δ 5.80 (m, 1H), 4.98 (dd, J = 17.1, 1.4 Hz, 1H), 4.92 (d, J = 10.2 Hz, 1H), 4.89 – 4.84 (m, 
1H), 2.27 (t, J = 7.5 Hz, 2H), 2.03 (q, J = 7.1 Hz, 2H), 1.65 – 1.58 (m, 2H), 1.50 (m, J = 
5.0 Hz, 4H), 1.43 – 1.20 (m, 48H), 0.88 (t, J = 7.0 Hz, 6H); 13C-NMR (151 MHz, CDCl3): 
δ 173.80, 139.27, 114.27, 74.16, 34.89, 34.32, 34.31, 33.93, 32.08, 32.05, 29.85, 29.84, 
29.82, 29.81, 29.78, 29.71, 29.69, 29.67, 29.62, 29.53, 29.51, 29.47, 29.35, 29.19, 29.05, 
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25.47, 25.45, 25.34, 22.84, 22.83, 14.25, 14.24; IR (film, cm-1) 1734; HRMS (APCI) calc. 







4-methylmorpholine N-oxide monohydrate (4.05 g, 30.0 mmol, 3 eq) was 
dehydrated by heating at 90°C under high vacuum overnight.  A 250 mL round-bottom 
flask equipped with stir bar was charged with olefin 8 (5.21 g, 10.0 mmol, 1 eq), the 
anhydrous 4-methyl N-oxide prepared above, and dry DCM (67 mL).  Stirring was 
initiated, affording a clear solution.  The reaction vessel was submerged in an ice-acetone 
bath and cooled to -10°C for 15 minutes before bubbling in a mixture of ozone/oxygen.  
Conversion was complete within 7 minutes.  The ozone generator was turned off and 
oxygen was bubbled through the solution for an additional 5 minutes.  The reaction vessel 
was allowed to warm to ambient temperature and aged for 1 hour.  The reaction was 
concentrated and the residue was dissolved in ethyl acetate (150 mL) and washed with 
water (100 mL) and brine (50 mL x 2), dried (sodium sulfate), filtered, and concentrated.  
The crude material was used in the next step without further purification. 
A 250 mL round-bottom flask equipped with stir bar and addition funnel was 
charged with the crude material above and dissolved in 2-methyl-2-butene (10.6 mL) and 
tert-butanol (50 mL).  Stirring was initiated, affording a clear solution.  The reaction vessel 
was cooled in an ice-water bath for 15 minutes before adding an aqueous solution of 
sodium phosphate monobasic monohydrate (5.52 g, 40.0 mmol, 4 eq) and sodium chlorite 
(technical grade, 80%, 4.52 g, 40.0 mmol, 4 eq) in deionized water (25 mL) dropwise via 
addition funnel.  The reaction was allowed to warm to ambient temperature and stirred 
overnight.   
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Peroxide test strips revealed the presence of peroxides.  After adding an aqueous 
solution of sodium bisulfite (6.24 g, 60.0 mmol, 6 eq) in deionized water (25 mL) dropwise 
via addition funnel and aging 30 minutes, peroxides were absent.  2-methyl-2-butene and 
tert-butanol were removed by rotavap with water bath at 50°C.  The residual aqueous layer 
was extracted with hexanes:ethyl acetate (50:50, 100 mL x 3).  Combined organics were 
washed with brine (100 mL), dried (sodium sulfate), filtered, and concentrated.  The crude 
product was purified by silica column chromatography, eluting with hexanes:EtOAc 
(90:10 to 70:30) to yield (1-R) (5.17 g. 96%) as an oil. 
 
R-9-PAHSA (1-R) 
Rf = 0.29 (silica gel, 80:20 hexanes:EtOAc, KMnO4); [α]23D 0.1000 (range: -
0.1160 to 0.3040) (c 1.00, CHCl3); 1H-NMR (600 MHz, CDCl3): δ 4.89 – 4.83 (m, 1H), 
2.34 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 1.65 – 1.58 (m, 4H), 1.50 (m, J = 4.8 Hz, 
4H), 1.27 (m, J = 22.8 Hz, 46H), 0.88 (t, J = 6.8 Hz, 6H); 13C-NMR (151 MHz, CDCl3): 
δ 179.05, 173.91, 74.17, 34.90, 34.31, 34.28, 33.97, 32.08, 32.05, 29.85, 29.82, 29.81, 
29.78, 29.71, 29.69, 29.67, 29.51, 29.46, 29.46, 29.35, 29.27, 29.12, 25.47, 25.40, 25.34, 
24.78, 22.84, 22.83, 14.26, 14.25; IR (film, cm-1): 1711, 1733, 3427; HRMS (ESI) calc. 





 A 25 mL round-bottom flask equipped with stir bar was charged with S-9-PAHSA 
S-1, dissolved in methanol (4 mL) and a few drops of hexanes. A solution of potassium 
hydroxide in methanol (4 mL, 10% w/v, 400 mg, 7.13 mmol, 15.5 eq) was added dropwise 
and the reaction was stirred at ambient temperature for 1 hour, then heated to 40°C and 
stirred overnight. The reaction was cooled to ambient temperature, then ice cubes were 
added followed by ice-cold 6M HCl until litmus paper turned red. The product was 
extracted with ethyl acetate (25 mL x 3) and combined organics were washed with brine 
(25 mL), dried (sodium sulfate), filtered, and concentrated. The residue was purified by 
flash chromatography, eluting with hexanes:ethyl acetate (90:10 to 50:50) to yield S-77 





General Procedures for FAHFA Library Synthesis and Chemical Biology Probes 
A) TBS protection of primary alcohols 
A round bottom flask equipped with stir bar was charged with primary alcohol (1 
eq) and dissolved in DCM (0.5 M), giving a clear, colorless solution. The solution was 
cooled in an ice water bath for 30 minutes before adding TBSCl (1.04 eq) in one portion, 
giving a clear, colorless solution. The reaction was aged for an additional 30 minutes at 0C 
before adding imidazole (1.1 eq) in one portion, affording an opaque, white heterogeneous 
mixture. The slurry was stirred for 12 hours before quenching with saturated aqueous 
ammonium chloride and deionized water. The biphasic mixture was transferred to a 
separatory funnel, extracted with ether (x 3). Combined organics were washed with brine, 
dried (sodium sulfate), filtered, and concentrated. The crude residue was purified by 
column chromatography, eluting with hexanes:ethyl acetate (99:1 to 95:5).  
B) Grignard Formation 
A round bottom flask charged with stir bar and magnesium turnings (2.5 eq) was 
flame dried under vacuum, cooled to ambeint temperature, flushed with nitrogen, sealed 
with a rubber septum, and maintained under a  nitrogen atmosphere. THF (1 M) was added 
via cannula. A solution of DIBAL (1.2 M in toluene, 0.025 eq) was added dropwise via 
syringe. The vessel was placed in an oil bath and warmed to 35 C for 15 minutes. Bromide 
(1 eq) was added NEAT via syringe pump (1 mmol/min), changing the color from clear to 
brown. After addition of of the bromide, the bath was heated to 50 C, then cooled to 
ambient temperature and used directly. 
C) Grignard Addition to epichlorohydrin 
A round bottom flask equipped with stir bar addition funnel was charged with 
copper iodide (10 mol%), flame dried under vacuum, cooled to ambeint temperature, 
flushed with nitrogen, sealed with arubber septum, and maintained under a  nitrogen 
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atmosphere. THF (0.5 M) and S-(+)-epichlorohydrin (1 eq) were added via cannula and 
syringe, respectively, giving an opaque, pink slurry. The apparatus was placed in a bath of 
dry ice-acetone and cooled for 30 minutes. The addition funnel was charged with Grignard 
via cannula. The Grignard (1.5 eq) was then added dropwise, changing color to a deep, 
dark blue. The vessel was allowed to warm to ambient temperature overnight. The reaction 
was carefully quenched dropwise with saturated aqueous ammonium chloride, then diluted 
with ethyl ether:hexanes (50:50). The heterogeneous mixture was stirred vigorously until 
the aqueous layer turned a brilliant, royal blue. The mixture was transferred to a separatory 
funnel and extracted with with ethyl ether:hexanes (50:50, x 3). Combined organics were 
washed with saturated aqueous ammonium chloride (x 2), brine, dried (sodium sulfate), 
filtered, and concentrated. The crude residue was purified by column chromatography, 
eluting with hexanes:ethyl acetate (90:10 to 80:20).  
D) Intramolecular Williamson Ether Synthesis 
A round bottom flask equipped with stir bar was charged with chlorohydrin (1 eq), 
ethyl ether (0.5 M), and sodium hydroxide (6 eq) and sealed. The heterogenous mixture 
was vigorously stirred (>1000 rpm) and monitored via aliquot NMR. Upon completion 
(usually within 4 hours), the heterogeneous mixture was filtered with a Buchner funnel, 
washing the filter cake with ethyl ether. The filtrate was transferred to a separatory funnel, 
washed with water and brine, dried (sodium sulfate), filtered, and concentrated before 
being used directly in the next step without further purification. 
E) Epoxide Opening 
A round bottom flask equipped with stir bar was charged with copper bromide (5 
mol%), flame dried under vacuum, cooled to ambeint temperature, flushed with nitrogen, 
sealed with arubber septum, and maintained under a  nitrogen atmosphere. Grignard (1.5 
eq) was added via syringe, giving a dark, opaque mixture. The vessel was placed in a bath 
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(70:30, water:methanol and dry ice) and cooled for thirty minutes after the cooling bath 
had formed a slurry/solid. A solution of epoxide (1 eq) in THF (1 M) was added dropwise 
via syringe pump (1 mL/min). The vessel was allowed to warm to ambient temperature 
overnight. The reaction was carefully quenched dropwise with saturated aqueous 
ammonium chloride, then diluted with ethyl ether:hexanes (50:50). The heterogeneous 
mixture was stirred vigorously until the aqueous layer turned a brilliant, royal blue. The 
mixture was transferred to a separatory funnel and extracted with with ethyl ether:hexanes 
(50:50, x 3). Combined organics were washed with saturated aqueous ammonium chloride 
(x 2), brine, dried (sodium sulfate), filtered, and concentrated. The crude residue was 
purified by column chromatography, eluting with hexanes:ethyl acetate (90:10 to 80:20).  
F) Silyl ether deprotection 
Taking no precaution to maintain a dry, inert atmosphere, a round bottom flask 
equipped with stir bar was charged with silyl ether (1 eq) and THF (0.5 M). The vessel was 
placed in an ice-water bath and cooled for 30 minutes. A solution of TBAF in THF (1.5 
eq/silyl ether) was added dropwise via syringe. Upon completion (TLC control), the 
reaction was quenched with ice cold 2 M hydrochloric acid. The mixture was transferred 
to a separatory funnel and extracted with ethyl acetate (x 3). Combined organics were 
washed with saturated aqueous sodium bicarbonate and brine, dried (sodium sulfate), 
filtered, and concentrated. The crude residue was purified by column chromatography, 
eluting with hexanes:ethyl acetate (80:20 to 60:40).  
G) TEMPO catalyzed oxidation of primary alcohols to aldehydes 
Taking no precaution to maintain a dry, inert atmosphere, a round bottom flask 
equipped with stir bar was charged with diol (1 eq) and DCM (0.1 M), affording a clear 
solution. TEMPO (10 mol%) was added in one portion, giving a clear, red-orange solution. 
DAIB (1.5 eq) was then added in one portion. Upon completion (TLC control), the reaction 
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was quenched with saturated aqueous sodium thiosulfate (NB! The aqueous sodium 
thiosulfate layer was more dense than the organic DCM layer). The mixture was transferred 
to a separatory funnel and extracted with ethyl acetate (x 3). Combined organics were 
washed with saturated aqueous sodium bicarbonate (x 3), brine, dried (sodium sulfate), 
filtered, and concentrated. The crude aldehyde residue was used in the next step without 
further purification. 
H) Pinnick Oxidation 
Taking no precaution to maintain a dry, inert atmosphere, a round bottom flask 
equipped with stir bar was charged with crude aldehyde (1 eq), 2-methyl-2-butene (10 eq), 
tert-butanol (0.1 M), giving a clear solution. The vessel was placed in an ice-water bath 
and cooled for 15 minutes. An aqueous solution of sodium chlorite (80% technical grade, 
4 eq) and sodium phosphate monobasic monohydrate (4 eq) was added dropwise. The 
biphasic mixture was vigorously stirred (>1000 rpm) in an effort to render the melange 
homogenous. Upon complete (TLC control), test strips revealed the presence of peroxides. 
The vessel was recooled in an ice-water bath for 15 minutes before adding dropwise an 
aqueous solution of sodium bisulfite (6 eq). Within 30 minutes the peroxides had been 
consumed. The 2-methyl-2-butene and tert-butanol were removed in vacuo with the 
heating bath at 50 C. The mixture was diluted with brine and ethyl acetate before transfer 
to a separatory funnel. The mixture was extracted with ethyl acetate (x 3), dried (sodium 
sulfate), filtered, and concentrated. The crude carboxylic acid was used in the next step 
without further purification. 
I) Fisher-Speier Esterification 
A round bottom flask equipped with stir bar and reflux condensor was charged with 
cude carboxylic acid (1 eq) and methanol (40 eq). The apparatus was sealed with a rubber 
septum and spurged with nitrogen for 5 minutes. Concentrated sulfuric acid (1 eq) was 
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added dropwise via syringe before placing the reaction vessel in an oil bath and heating to 
reflux. Upon completion (TLC control), the reaction was cooled to ambient temperature 
and carefully quenched by adding solid sodium bicarbonate (4 eq) in portions. The mixture 
was gravity filtered and the filter cake washed with methanol. The filtrate was concentrated 
and the residue was dissolved in water and ethyl acetate before transfer toa  separatory 
funnel. The mixture was extracted with ethyl acetate (x 3). Combined organics were 
washed with brine, dried (sodium sulfate), filtered, and concentrated. The crude residue 
was purified by column chromatography, eluting with hexanes:ethyl acetate (85:15 to 
70:30).  
J) Mitsunobu Reaction 
A round bottom flask equipped with stir bar was sequentially charged with 
secondary alcohol (1 eq), 4-nitrobenzoic acid (4 eq), benzene (0.1 M), and tributyl 
phosphine (4 eq). The vessel was placed in an ice-water bath and cooled for 30 minutes 
before adding dropwise via syringe diisopropylazadicarboxylate (4 eq). The reaction was 
allowed to warm to ambient temperature ovenight and diluted with hexanes. The mixture 
was transferred to a separatory funnel and washed with 2 M sodium hydroxide (x 3) and 
brine, dried (sodium sulfate), filterted, and concentrated. The residue was filtered through 
a plug of silica, eluting with hexanes:ethyl acetate (95:5). After concentrating the solvent 
in vacuo, the residue was used in the next step without further purification. 
K) Chemoselective Cleavage of Aryl Ester 
A round bottom flask equipped with stir bar was charged with diester (1 eq) and 
methanol (x M). Solid potassium carbonate (1 eq) was added in one portion. Upon 
completion (TLC control) the solvent was removed in vacuo. The residue was dissolved in 
ethyl acetate and brine with acetic acid (2 eq). The mixture was transferred toa  separatory 
funnel and extracted with ethyl aceteate (x 3). Combined organics were washed with brine, 
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dried (sodium sulfate), filtered, and concentratated. The crude residue was filtered through 
a plug of silica, eluting with hexanes:ethyl acetate (95:5). Solvent was removed in vacuo 
and used in the next step without further purification.  
L) Yamaguchi Esterification 
A round bottom flask equipped with stir bar was charged with methyl 
hydroxystearate (1 eq), carboxylic acid (1.25 eq), and benzene (0.1 M). After dissolution, 
2,4,6-trichlorobenzoyl chloride (1.25 eq) was added dropwise via syringe and the reaction 
aged 15 minutes. Triethylamine (6.25 eq) was added dropwise via syringe, followed by 
DMAP (12.5 mol%) in one portion. The reaction was allowed to stir overnight, diluted 
with hexanes and transferred to a separatory funnel. The organic layer was washe with 
aqueous hydrochloric acid (2 M), brine, dried (sodium sulfate), filtered, and concentrated. 
The residue was purified by column chromatography, eluting with hexanes:ethyl acetate 
(95:5 to 90:10). 
M) Chemoselective Saponification of Methyl Esters 
A round bottom flask equipped with stir bar was charged with methyl ester (1 eq) 
and dissolved in THF (0.1 M). Aqueous lithium hydroxide (1 M, 2 eq) was added dropwise 
via syringe. Upon completion (TLC control), the reaction was diluted with ethyl acetate 
and brine with acetic acid (3 eq). The mixture was transferred to a separatory funnel and 
extracted with ethyl acetate (x 3). Combined organics were dried (sodium sulfate), filtered, 
and concentrated. The residue was purified by column chromatography, eluting with 




Following General Procedure A for the TBS protection of primary alcohols, 
primary alcohol 80 gave TBS protected 81 as a clear, colorless oil. Spectra were in 




Following General Procedures B and C for the formation of Grignards and their 
addition to epichlorohydrin, bromide 81 gave chlorohydrin 82 as a clear, colorless oil.  
Rf  = 0.18 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.82 – 3.76 (m, J = 6.9, 3.8 Hz, 1H), 3.63 – 3.59 
(m, 3H), 3.46 (dd, J = 11.1, 7.0 Hz, 1H), 1.57 – 1.36 (m, 6H), 0.87 (s, 9 H), 0.03 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 71.49, 63.05, 50.55, 34.01, 32.60, 26.07, 22.01, 
18.46, -5.18. 




Following General Procedures D, B, and E for the intramolecular Williamson ether 
synthesis, Grignard formation, and epoxide opening, respectively, 82 gave 84 as a white 
solid. 
Rf  = 0.38 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.65 – 3.55 (m, 3H), 1.58 – 1.21 (m, 32H), 0.90 – 
0.86 (m, 12H), 0.05 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 72.04, 63.30, 37.60, 37.29, 32.90, 32.07, 29.82, 
29.51, 26.13, 26.11, 25.79, 22.85, 22.05, 18.52, 14.29, -5.11, -5.14. 





Following General Procedure F for silyl ether deprotection, 84 gave 85 as a white 
solid. 
Rf  = 0.09 (silica gel, 70:30, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.66 (t, J = 6.5 Hz, 2H), 3.64 – 3.58 (m, 1H), 1.65 
– 1.22 (m, 36H), 0.88 (t, J = 7.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 72.04, 63.01, 37.69, 37.16, 32.78, 32.07, 29.84, 
29.82, 29.81, 29.80, 29.78, 29.76, 29.51, 25.81, 22.84, 21.97, 14.29. 





Taking no precaution to maintain a dry, inert atmosphere, a round bottom flask 
equipped with stir bar was charged with diol 86 (2.86 g, 10 mmol, 1 eq), DCM (100 mL, 
0.1 M), TEMPO (0.31 g, 2.0 mmol, 20 mol%), and DAIB (10.2 g, 31.6 mmol, 3.16 eq). 
Upon complete (TLC control), the reaction was quenched with saturated aqueous sodium 
thiosulfate (NB! The aqueous sodium thiosulfate layer was more dense than the organic 
DCM layer). The mixture was transferred to a separatory funnel and extracted with ethyl 
acetate (x 3). Combined organics were washed with saturated aqueous sodium bicarbonate 
(x 3), brine, dried (sodium sulfate), filtered, and concentrated. The residue was purified by 
column chromatography, eluting with hexanes:ethyl acetate (90:10 to 80:20), giving 






Taking no precaution to maintain a dry, inert atmosphere, a round bottom flask 
equipped with stir bar was charged with lactone 86 (1 eq), methanol (0.1 M), and 
triethylamine (3 eq). Upon completion (TLC control), volatiles were removed in vacuo, 
yielding analytically pure methyl hydroxystearate 87. 
Rf  = 0.26 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (599 MHz, CDCl3) δ 3.68 (s, 3H), 3.63 – 3.56 (m, 1H), 2.35 (t, J = 7.4 
Hz, 2H), 1.83 – 1.22 (m, 42H), 0.88 (t, J = 7.0 Hz, 3H). 





 Following General Procedures J and K for the Mitsunobu reaction, and 
chemoselective saponification of aryl esters, respectively, S-87 gave R-87.  
Rf  = 0.26 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (599 MHz, CDCl3) δ 3.68 (s, 3H), 3.63 – 3.56 (m, 1H), 2.35 (t, J = 7.4 
Hz, 2H), 1.83 – 1.22 (m, 42H), 0.88 (t, J = 7.0 Hz, 3H). 





Following General Procedure L for the Yamaguchi esterification, 87 gave 89 as a 
white solid. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 4.91 – 4.84 (m, 1H), 3.66 (s, 3H), 2.31 (td, J = 7.4, 
3.0 Hz, 2H), 2.28 (t, J = 7.5 Hz, 2H), 1.69 – 1.45 (m, 12H), 1.33 – 1.21 (m, 47H), 0.88 (t, 
J = 7.0 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.99, 173.85, 73.52, 51.69, 34.81, 34.18, 33.91, 
33.59, 32.07, 29.85, 29.81, 29.78, 29.73, 29.69, 29.65, 29.52, 29.45, 29.34, 25.42, 25.28, 
22.85, 20.84, 14.28. 





Following General Procedure L for the Yamaguchi esterification, 87 gave 90 as an 
oil. 
Rf  = 0.54 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.44 – 5.29 (m, 2H), 4.93 – 4.84 (m, J = 5.8 Hz, 
2H), 3.66 (s, 3H), 2.36 – 2.23 (m, 4H), 2.11 – 1.92 (m, 4H), 1.72 – 1.43 (m, 9H), 1.43 – 
1.18 (m, 45H), 0.87 (t, J = 6.8 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.81, 130.13, 129.89, 73.53, 51.69, 34.79, 34.17, 
33.90, 33.58, 32.07, 32.05, 29.91, 29.85, 29.83, 29.80, 29.73, 29.69, 29.67, 29.64, 29.52, 
29.47, 29.35, 29.31, 29.28, 27.36, 27.31, 25.43, 25.26, 22.84, 20.84, 14.28. 




Rf  = 0.50 (silica gel, 90:10, hexanes:ethyl acetate) 
Following General Procedure L for the Yamaguchi esterification, 87 gave 91 as an 
oil. 
1H NMR (600 MHz, CDCl3) δ 5.43 – 5.28 (m, 4H), 4.91 – 4.83 (m, J = 11.9, 5.9 
Hz, 1H), 3.66 (s, 3H), 2.77 (t, J = 6.7 Hz, 2H), 2.35 – 2.25 (m, 4H), 2.04 (q, J = 6.9 Hz, 
4H), 1.69 – 1.45 (m, 9H), 1.38 – 1.21 (m, 38H), 0.88 (q, J = 6.5 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.98, 173.80, 130.36, 130.19, 128.16, 128.03, 
73.54, 51.69, 34.79, 34.17, 33.90, 33.58, 32.07, 31.66, 29.84, 29.82, 29.80, 29.76, 29.73, 
29.69, 29.64, 29.51, 29.49, 29.35, 29.30, 29.29, 27.33, 25.76, 25.42, 25.25, 22.84, 22.72, 
20.84, 14.28, 14.23. 
HRMS: HR‐ESI‐TOFMS calc. for  [C37 H68 O4 Na]+  : 599.5010 obs. 599.5008  
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Following General Procedure L for the Yamaguchi esterification, 87 gave 92 as an 
oil. 
Rf  = 0.48 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.28 (m, 6H), 4.90 – 4.85 (m, 1H), 3.66 (s, 
3H), 2.80 (s, 4H), 2.35 – 2.24 (m, J = 19.8, 16.5, 8.4 Hz, 4H), 2.12 – 2.01 (m, 4H), 1.70 – 
1.45 (m, 8H), 1.38 – 1.18 (m, 32H), 0.97 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 173.97, 173.79, 132.09, 130.41, 128.41, 128.38, 
127.84, 127.23, 73.54, 51.68, 34.78, 34.17, 33.90, 33.57, 32.07, 29.84, 29.82, 29.80, 29.73, 
29.69, 29.64, 29.51, 29.35, 29.30, 29.28, 27.35, 25.74, 25.66, 25.42, 25.24, 22.84, 20.84, 
20.69, 14.43, 14.28. 
HRMS: HR‐ESI‐TOFMS calc. for  [C37 H66 O4 Na]+: 597.4853 obs. 597.4850  
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Following General Procedure L for the Yamaguchi esterification, 87 gave 93 as an 
oil. 
Rf  = 0.48 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.43 – 5.30 (m, 6H), 4.88 (dd, J = 11.9, 5.9 Hz, 1H), 
3.66 (s, 3H), 2.80 (t, J = 5.7 Hz, 4H), 2.35 – 2.26 (m, 4H), 2.07 (dq, J = 21.0, 7.0 Hz, 4H), 
1.69 – 1.19 (m, 42H), 0.88 (q, J = 6.6 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.96, 173.61, 130.58, 129.77, 128.53, 128.31, 
128.21, 127.71, 73.60, 51.69, 34.65, 34.17, 33.89, 33.57, 32.07, 31.65, 29.84, 29.82, 29.80, 
29.73, 29.69, 29.64, 29.51, 29.47, 29.27, 27.35, 27.02, 25.76, 25.75, 25.43, 24.86, 22.84, 
22.72, 20.83, 14.28, 14.23. 




Following General Procedure M for the chemoselective saponification of methyl 
esters, 90 gave 95 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 70:30, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.44 – 5.33 (m, 2H), 4.91 (s, 1H), 2.31 (t, J = 7.4 
Hz, 2H), 2.03 (d, J = 5.8 Hz, 3H), 1.73 – 1.20 (m, 58H), 0.91 (t, J = 6.8 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.88, 130.13, 129.90, 73.53, 34.79, 34.19, 33.53, 
32.08, 32.06, 29.92, 29.85, 29.83, 29.81, 29.74, 29.70, 29.68, 29.65, 29.52, 29.48, 29.35, 
29.31, 29.29, 27.36, 27.32, 25.44, 25.26, 22.85, 14.29. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 91 gave 96 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.41 – 5.28 (m, 4H), 4.93 – 4.84 (m, 1H), 2.77 (t, J 
= 6.8 Hz, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.04 (q, J = 7.0 Hz, 4H), 1.76 – 1.13 (m, 49H), 0.88 
(q, J = 6.5 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.88, 130.36, 130.20, 128.16, 128.04, 73.56, 
34.79, 34.18, 33.57, 32.07, 31.67, 29.85, 29.83, 29.81, 29.76, 29.74, 29.70, 29.65, 29.52, 
29.50, 29.36, 29.31, 29.30, 27.34, 25.76, 25.44, 25.25, 22.85, 22.73, 14.29, 14.24. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 92 gave 97 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 93 gave 98 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.45 – 5.23 (m, 6H), 4.92 – 4.84 (m, 1H), 2.81 (t, J 
= 6.0 Hz, 4H), 2.43 – 2.31 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.07 (tt, J = 13.7, 6.9 Hz, 4H), 
1.72 – 1.17 (m, 49H), 0.97 (t, 3H), 0.88 (t, J = 7.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 173.91, 132.10, 130.42, 128.42, 128.39, 127.84, 
127.24, 73.62, 34.80, 34.18, 33.59, 32.08, 29.86, 29.84, 29.81, 29.75, 29.71, 29.66, 29.52, 
29.36, 29.31, 29.30, 27.36, 25.75, 25.66, 25.45, 25.25, 22.85, 20.70, 14.44, 14.29. 






Following General Procedure A for the TBS protection of primary alcohols, 
primary alcohol 100 gave TBS protected 101 as a clear, colorless oil. Spectra were in 





Following General Procedures B and C for the formation of Grignards and their 
addition to epichlorohydrin, bromide 101 gave chlorohydrin 102 as a clear, colorless oil.  
Rf  = 0.30 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.82 – 3.77 (m, 1H), 3.64 (dd, J = 11.1, 3.2 Hz, 1H), 
3.59 (t, J = 6.6 Hz, 2H), 3.48 (dt, J = 11.1, 5.4 Hz, 1H), 1.57 – 1.26 (m, 14H), 0.89 (s, 9H), 
0.04 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 71.58, 63.44, 50.76, 34.34, 32.98, 29.61, 29.58, 
29.47, 26.13, 26.12, 25.90, 25.65, -5.11. 




Following General Procedures D, B, and E for the intramolecular Williamson ether 
synthesis, Grignard formation, and epoxide opening, respectively, 102 gave 44 as a white 
solid. 
Rf  = 0.38 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.61 – 3.55 (m, 3H), 1.53 – 1.21 (m, 31H), 0.92 – 
0.85 (m, 12H), 0.04 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 72.10, 63.44, 37.61, 37.59, 32.99, 32.03, 29.86, 
29.79, 29.78, 29.74, 29.72, 29.52, 29.47, 26.12, 26.11, 25.91, 25.80, 25.78, 22.82, 18.50, 
14.26, -5.13, -5.13, -5.14, -5.14. 




Following General Procedure F for silyl ether deprotection, 44 gave 103 as a white 




Following General Procedures G, H, and I for the chemoselective oxidation of 
primary alcohols to aldehydes, Pinnick oxidation, and Fisher-Speier esterification, 




Following General Procedures J and K for the Mitsunobu reaction, and 
chemoselective saponification of aryl esters, respectively, S-104 gave R-104. Specta were 





Following General Procedure L for the Yamaguchi esterification, 104 gave 105 as 
a white solid. 
Rf  = 0.49 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 4.82 – 4.75 (m, 1H), 3.60 (s, 3H), 2.25 – 2.17 (m, 
4H), 1.57 – 1.13 (m, 57H), 0.81 (t, J = 6.8 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.46, 173.90, 74.14, 51.61, 34.88, 34.29, 34.27, 
34.21, 32.07, 32.04, 29.85, 29.81, 29.78, 29.71, 29.69, 29.67, 29.52, 29.48, 29.47, 29.34, 
29.30, 29.20, 25.46, 25.41, 25.33, 25.05, 22.84, 22.83, 14.28. 




Following General Procedure L for the Yamaguchi esterification, 104 gave 106 as 
an oil. 
Rf  = 0.49 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.39 – 5.30 (m, 2H), 4.88 – 4.83 (m, 1H), 3.66 (s, 
3H), 2.28 (dt, J = 12.6, 7.6 Hz, 4H), 2.06 – 1.97 (m, 4H), 1.64 – 1.19 (m, 52H), 0.90 – 0.85 
(m, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.46, 173.87, 130.13, 129.90, 74.16, 51.62, 
34.86, 34.29, 34.27, 34.22, 32.05, 32.04, 29.91, 29.85, 29.70, 29.68, 29.47, 29.36, 29.31, 
29.29, 29.21, 27.36, 27.31, 25.46, 25.41, 25.31, 25.05, 22.83, 14.28. 





Following General Procedure L for the Yamaguchi esterification, 104 gave 107 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.28 (m, 4H), 4.89 – 4.82 (m, 1H), 3.66 (s, 
3H), 2.77 (t, J = 6.7 Hz, 2H), 2.33 – 2.23 (m, 4H), 2.04 (q, J = 6.9 Hz, 4H), 1.66 – 1.18 (m, 
48H), 0.88 (q, J = 6.9 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.46, 173.85, 130.36, 130.20, 128.16, 128.04, 
74.17, 51.62, 34.86, 34.29, 34.26, 34.21, 32.04, 31.67, 29.76, 29.70, 29.68, 29.49, 29.48, 
29.46, 29.36, 29.30, 29.20, 27.34, 25.76, 25.46, 25.41, 25.30, 25.05, 22.83, 22.73, 14.28, 
14.24. 




Following General Procedure L for the Yamaguchi esterification, 104 gave 108 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.28 (m, 6H), 4.90 – 4.80 (m, 1H), 3.66 (s, 
3H), 2.80 (s, 4H), 2.28 (dt, J = 12.0, 7.6 Hz, 4H), 2.12 – 2.00 (m, 4H), 1.65 – 1.18 (m, 
42H), 0.97 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 174.46, 173.85, 132.10, 130.42, 128.41, 128.38, 
127.84, 127.24, 74.16, 51.62, 34.86, 34.29, 34.26, 34.21, 32.04, 29.85, 29.74, 29.70, 29.68, 
29.48, 29.46, 29.36, 29.30, 29.20, 27.35, 25.74, 25.66, 25.46, 25.41, 25.30, 25.05, 22.83, 
20.69, 14.44, 14.28. 




Following General Procedure L for the Yamaguchi esterification, 104 gave 109 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 




Following General Procedure M for the chemoselective saponification of methyl 
esters, 106 gave 111 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.34 (d, J = 1.5 Hz, 2H), 4.90 – 4.82 (m, 1H), 2.34 
(t, J = 7.1 Hz, 2H), 2.27 (t, J = 7.1 Hz, 2H), 2.00 (d, J = 5.8 Hz, 4H), 1.67 – 1.18 (m, 65H), 
0.87 (t, J = 6.9 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.93, 130.13, 129.89, 74.18, 34.87, 34.29, 34.25, 
32.04, 29.91, 29.85, 29.70, 29.69, 29.47, 29.44, 29.36, 29.31, 29.29, 29.27, 29.11, 27.36, 
27.31, 25.47, 25.40, 25.31, 24.79, 22.83, 14.28. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 107 gave 112 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.29 (m, 4H), 4.90 – 4.82 (m, 1H), 2.77 (t, J 
= 6.8 Hz, 2H), 2.35 (t, J = 6.6 Hz, 2H), 2.28 (dd, J = 16.8, 9.4 Hz, 2H), 2.04 (q, J = 6.9 Hz, 
4H), 1.65 – 1.18 (m, 48H), 0.88 (q, J = 7.0 Hz, 6H). 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.29 (m, 4H), 4.90 – 4.82 (m, 1H), 2.77 (t, J 
= 6.8 Hz, 2H), 2.35 (t, J = 6.6 Hz, 2H), 2.28 (dd, J = 16.8, 9.4 Hz, 2H), 2.04 (q, J = 6.9 Hz, 
4H), 1.65 – 1.18 (m, 48H), 0.88 (q, J = 7.0 Hz, 6H). 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 108 gave 113 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.44 – 5.27 (m, 6H), 4.89 – 4.82 (m, 1H), 2.80 (s, 
4H), 2.35 (t, J = 6.9 Hz, 2H), 2.28 (dd, J = 17.0, 9.5 Hz, 2H), 2.12 – 2.00 (m, 4H), 1.66 – 
1.19 (m, 43H), 0.97 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 173.90, 132.10, 130.42, 128.42, 128.39, 127.84, 
127.24, 34.86, 34.29, 34.25, 32.04, 29.74, 29.71, 29.68, 29.47, 29.44, 29.36, 29.31, 29.30, 
29.27, 29.11, 27.35, 25.75, 25.66, 25.47, 25.40, 25.30, 24.79, 22.83, 20.70, 14.44, 14.28. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 109 gave 114 as a clear, slightly yellow oil. 
Rf  = 0.34 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.43 – 5.30 (m, 6H), 4.89 – 4.83 (m, 1H), 2.84 – 
2.77 (m, 4H), 2.35 (dd, J = 14.1, 6.7 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 2.11 – 2.02 (m, 4H), 
1.68 – 1.20 (m, 41H), 0.88 (q, J = 7.1 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.71, 130.59, 129.80, 128.53, 128.30, 128.22, 
127.72, 74.24, 34.72, 34.28, 34.25, 32.04, 31.66, 29.70, 29.69, 29.68, 29.47, 29.46, 29.45, 
29.27, 29.11, 27.35, 27.03, 25.76, 25.75, 25.47, 25.41, 24.91, 24.77, 22.83, 22.73, 14.28, 
14.24. 





Following General Procedure A for the TBS protection of primary alcohols, 
primary alcohol 115 gave TBS protected 116 as a clear, colorless oil. Spectra were 





Following General Procedures B and C for the formation of Grignards and their 
addition to epichlorohydrin, bromide 116 gave chlorohydrin 117 as a clear, colorless oil.  
Rf  = 0.32 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.80 (ddd, J = 12.5, 7.5, 3.3 Hz, 1H), 3.66 – 3.62 
(m, 1H), 3.59 (t, J = 6.7 Hz, 2H), 3.50 – 3.45 (m, 1H), 1.58 – 1.23 (m, 27H), 0.89 (s, 9H), 
0.04 (s, 6H).  
13C NMR (151 MHz, CDCl3) δ 71.59, 63.50, 50.78, 34.35, 33.03, 29.77, 29.75, 
29.73, 29.69, 29.64, 29.59, 26.13, 25.94, 25.67, -5.11. 





Following General Procedures D, B, and E for the intramolecular Williamson ether 
synthesis, Grignard formation, and epoxide opening, respectively, 117 gave 119 as a white 
solid. 
Rf  = 0.38 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.63 – 3.55 (m, 3H), 1.58 – 1.22 (m, 36H), 0.089 
(s, 12H), 0.04 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 72.19, 63.51, 37.63, 37.58, 33.03, 32.06, 29.86, 
29.78, 29.75, 29.60, 26.14, 25.94, 25.81, 25.48, 22.81, 14.22, -5.11. 





Following General Procedure F for silyl ether deprotection, 119 gave 120 as a white 
solid. 
Rf  = 0.31 (silica gel, 70:30, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 3.65 (t, J = 8.7, 4.7 Hz, 2H), 3.63 – 3.56 (m, 1H), 
1.61 – 1.23 (m, 35H), 0.90 (t, J = 9.3, 4.6 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 72.19, 63.26, 37.62, 37.59, 32.94, 32.06, 29.84, 
29.75, 29.72, 29.70, 29.56, 25.86, 25.80, 25.48, 22.81, 14.22. 




Following General Procedures G, H, and I for the chemoselective oxidation of 
primary alcohols to aldehydes, Pinnick oxidation, and Fisher-Speier esterification, 






Following General Procedures J and K for the Mitsunobu reaction, and 
chemoselective saponification of aryl esters, respectively, S-121 gave R-121. Spectra were 







Following General Procedure L for the Yamaguchi esterification, 121 gave 122 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 4.89 – 4.83 (m, 1H), 3.66 (s, 3H), 2.29 (dt, J = 14.6, 
7.5 Hz, 4H), 1.65 – 1.19 (m, 62H), 0.87 (t, J = 6.5 Hz, 6H). 
1H NMR (600 MHz, CDCl3) δ 4.89 – 4.83 (m, 1H), 3.66 (s, 3H), 2.29 (dt, J = 14.6, 
7.5 Hz, 4H), 1.65 – 1.19 (m, 62H), 0.87 (t, J = 6.5 Hz, 6H). 




Following General Procedure L for the Yamaguchi esterification, 121 gave 123 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.37 – 5.31 (m, 2H), 4.90 – 4.83 (m, 1H), 3.66 (s, 
3H), 2.33 – 2.24 (m, 4H), 2.03 – 1.98 (m, 4H), 1.65 – 1.19 (m, 55H), 0.87 (t, J = 6.1 Hz, 
6H). 
13C NMR (151 MHz, CDCl3) δ 174.53, 173.87, 130.12, 129.90, 74.22, 51.61, 
34.87, 34.30, 34.26, 34.24, 32.05, 31.86, 29.91, 29.85, 29.70, 29.69, 29.67, 29.59, 29.47, 
29.41, 29.36, 29.30, 29.29, 27.36, 27.31, 25.48, 25.31, 25.13, 25.10, 22.84, 22.71, 14.28, 
14.17. 





Following General Procedure L for the Yamaguchi esterification, 121 gave 124 as 
an oil. 
Rf  = 0.51 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.40 – 5.32 (m, 4H), 4.86 (p, J = 6.2 Hz, 1H), 3.66 
(s, 3H), 2.77 (t, J = 6.7 Hz, 2H), 2.32 – 2.25 (m, 4H), 2.04 (t, J = 7.0 Hz, 4H), 1.65 – 1.19 
(m, 49H), 0.88 (q, J = 7.0 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.52, 173.86, 130.36, 130.20, 128.15, 128.04, 
74.22, 51.61, 34.87, 34.30, 34.26, 34.24, 31.86, 31.67, 29.75, 29.70, 29.69, 29.59, 29.49, 
29.41, 29.36, 29.30, 27.34, 25.76, 25.48, 25.31, 25.13, 25.10, 22.73, 22.71, 14.24, 14.17. 





Following General Procedure L for the Yamaguchi esterification, 121 gave 125 as 
an oil. 
Rf  = 0.49 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.41 – 5.29 (m, 6H), 4.86 (p, J = 6.1 Hz, 1H), 3.66 
(s, 3H), 2.80 (s, 4H), 2.32 – 2.25 (m, 4H), 2.10 – 2.02 (m, 4H), 1.65 – 1.19 (m, 43H), 0.97 
(t, J = 7.5 Hz, 3H), 0.87 (t, J = 6.5 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 174.53, 173.86, 132.10, 130.42, 128.41, 128.39, 
127.84, 127.24, 74.23, 51.62, 34.87, 34.30, 34.26, 34.24, 31.86, 29.74, 29.69, 29.59, 29.41, 
29.36, 29.30, 27.35, 25.75, 25.66, 25.48, 25.31, 25.13, 25.10, 22.71, 20.69, 14.44, 14.17. 






Following General Procedure L for the Yamaguchi esterification, 121 gave 126 as 
an oil. 
Rf  = 0.46 (silica gel, 90:10, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.41 – 5.28 (m, 6H), 4.86 (p, J = 6.1 Hz, 1H), 3.66 
(s, 3H), 2.80 (t, J = 5.8 Hz, 4H), 2.33 – 2.26 (m, 4H), 2.12 – 2.03 (m, 4H), 1.68 – 1.19 (m, 
41H), 0.88 (dd, J = 14.6, 7.0 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.52, 173.67, 130.58, 129.80, 128.52, 128.29, 
128.22, 127.72, 74.28, 51.61, 34.73, 34.29, 34.26, 34.23, 31.85, 31.66, 29.70, 29.69, 29.59, 
29.47, 29.41, 29.29, 29.27, 27.35, 27.03, 25.75, 25.48, 25.13, 25.10, 24.92, 22.72, 22.70, 
14.23, 14.17. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 122 gave 127 as a white solid. 
Rf  = 0.30 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 4.90 – 4.83 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 2.27 
(t, J = 7.5 Hz, 2H), 1.66 – 1.18 (m, 61H), 0.87 (td, J = 6.9, 1.6 Hz, 6H). 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 123 gave 128 as a clear, slightly yellow oil. 
Rf  = 0.30 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.40 – 5.30 (m, 2H), 4.91 – 4.82 (m, 1H), 2.34 (t, J 
= 7.3 Hz, 2H), 2.27 (t, J = 7.4 Hz, 2H), 2.04 – 1.96 (m, 4H), 1.62 (dd, J = 14.2, 7.1 Hz, 
4H), 1.49 (s, 4H), 1.27 (dd, J = 21.0, 8.8 Hz, 46H), 0.87 (t, J = 6.1 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.94, 130.13, 129.90, 74.25, 34.88, 34.30, 34.24, 
32.05, 31.86, 29.91, 29.85, 29.67, 29.55, 29.47, 29.36, 29.30, 29.29, 29.18, 27.36, 27.31, 
25.47, 25.31, 25.13, 24.82, 22.84, 22.71, 14.28, 14.17. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 124 gave 129 as a clear, slightly yellow oil. 
Rf  = 0.30 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.44 – 5.26 (m, 4H), 4.89 – 4.83 (m, 1H), 2.76 (t, J 
= 6.6 Hz, 2H), 2.34 (t, J = 7.0 Hz, 2H), 2.27 (t, J = 7.3 Hz, 2H), 2.08 – 2.00 (m, 4H), 1.66 
– 1.16 (m, 50H), 0.87 (dd, J = 13.7, 6.7 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 179.98, 173.94, 130.34, 130.18, 128.15, 128.03, 
74.26, 34.87, 34.29, 34.23, 34.18, 31.85, 31.66, 29.75, 29.67, 29.56, 29.49, 29.37, 29.35, 
29.29, 29.19, 27.33, 25.75, 25.46, 25.30, 25.12, 24.82, 22.72, 22.70, 14.23, 14.16. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 125 gave 130 as a clear, slightly yellow oil. 
Rf  = 0.30 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.42 – 5.28 (m, 6H), 4.90 – 4.84 (m, 1H), 2.80 (s, 
4H), 2.35 (t, J = 7.5 Hz, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.11 – 2.02 (m, 4H), 1.67 – 1.20 (m, 
44H), 0.97 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 179.55, 173.84, 131.97, 130.30, 128.29, 128.26, 
127.72, 127.12, 74.16, 34.75, 34.17, 34.12, 33.99, 31.74, 31.73, 29.61, 29.56, 29.44, 29.25, 
29.23, 29.18, 29.17, 29.07, 27.23, 25.62, 25.54, 25.35, 25.18, 25.00, 24.70, 22.58, 20.57, 
14.31, 14.05. 





Following General Procedure M for the chemoselective saponification of methyl 
esters, 126 gave 131 as a clear, slightly yellow oil. 
Rf  = 0.30 (silica gel, 80:20, hexanes:ethyl acetate) 
1H NMR (600 MHz, CDCl3) δ 5.45 – 5.28 (m, 6H), 4.92 – 4.81 (m, 1H), 2.86 – 
2.76 (m, 4H), 2.34 (t, J = 7.5 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 2.12 – 2.02 (m, 4H), 1.68 – 
1.20 (m, 41H), 0.88 (dd, J = 15.3, 7.0 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 173.73, 130.59, 129.80, 128.52, 128.29, 128.23, 
127.72, 74.32, 34.74, 34.29, 34.23, 31.86, 31.66, 29.67, 29.55, 29.47, 29.36, 29.27, 29.18, 
27.36, 27.03, 25.76, 25.75, 25.48, 25.13, 24.93, 24.83, 22.73, 22.71, 14.24, 14.18. 
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